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Abstract
Human immunodeficiency virus type 1 (HIV-1) emerged in the human population shortly after
the turn of the 19th century. Distribution of HIV-1 across the globe over the past 30–35 years
can be traced to founder events with primordial HIV strains from sub-Saharan Africa. Even
considering the burden of HIV in Africa, our knowledge of HIV-1 disease is still largely limited
to subtype B HIV-1, a strain responsible for 3 million infections in North America and Europe
as compared to the 33 million that are infected with HIV-1 subtypes A, C, D, and circulating
and unique recombinant forms.
This dissertation analyzes data and archived samples from a cohort of HIV+ women in Uganda
and Zimbabwe to assess the role of HIV-1 Group M subtype in disease progression, viral
replicative fitness and cellular entry efficiency. Generalized estimating equation models are
employed to calculate average rates of CD4+ T-cell loss over the course of disease, investigate
circulating viral load, and compare depletion of memory T-cell subsets in CD4+ and CD8+ Tcells. Fluorescent tissue culture assays of HIV-1 entry were used to phenotypically evaluate
entry efficiency and its association with replicative fitness.
Ugandan and Zimbabwean women infected with HIV-1 subtype C had 2.5-fold slower rates of
CD4 T-cell declines and higher frequencies of long-term non-progression than those infected
with subtype A or D, a difference not associated with any other clinical parameters. Relative
replicative fitness and entry efficiency of HIV-1 variants directly correlated with virulence in
the patients, subtype D > A > C. These relationships were maintained in both assays evaluating
HIV-induced cell-fusion rates, viral particle entry rates and CD4 receptor affinity.
The primary burden of HIV infection is placed on T-cell memory populations that are focal
points for progeny virion production, the latent proviral reservoir, and immune activation. All
subtypes depleted effector memory T-cells preferentially, however subtype D infections lost
these cells at about twice the rate of subtype C infections. Finally, subtype D was found to
uniquely deplete CD8+ memory T-cells.
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Chapter 1
Introduction
Approximately 35 million people have died from HIV/AIDS. Over 37 million more are
currently infected [1]. The past, present and future of the entire African continent have
been shaped by it. But for the first time, HIV appears beatable: new infections have slowed,
global prevention initiatives funded and implemented, and science has made tremendous
progress controlling and preventing infections. Whether the future holds a vaccine,
sterilizing cure or additional international programs pushing to prevent transmissions, the
tide has already turned. It’s only in the light of this potential that we can look back to learn
from this disease, to inform future HIV policies, but also to prevent other zoonotic, or
animal borne diseases in the future.

1.1.

The Cut Hunter Hypothesis

A young man, starving and exhausted from overwork in the rubber tree plantations of the
Belgian Congo, hunts in the jungle [2, 3]. It’s approximately 1931 (best estimates place it
between 1915 and 1941) and food has become so scarce that he is forced to expand his
typical dietary choices [4-7]. Bush meat, or the practice of hunting and eating jungle
animals, has become a mainstay in his diet. Chimpanzees were a particularly common prey
since they are large, relatively abundant, and accustomed to human interaction along the
edges of the jungle [8-12]. In this account, the hunter is pursuing the local chimpanzee
subspecies, the Central chimpanzee (Pan troglodytes troglodytes), armed with rudimentary
equipment: dull knives or sharpened metal implements. Exhaustion provides enough of an
impediment for the hunter to make a deadly mistake. While killing a chimpanzee the hunter
injures himself, and the strain of the simian immunodeficiency virus (SIV) this chimpanzee
harbors was able to reach his bloodstream. Unaware of the virus he is carrying, this man
disregards the mild fever he gets over the next week. These symptoms resolve without
long-term complications. Sometime within the next few years, this man leaves the rubber
plantations and relocates by train to the local metropolitan center of Kinshasa, Zaire (now
the Democratic Republic of the Congo or DRC) [10, 13]. The future will call him patient
zero, the first human to begin spreading the human immunodeficiency virus (HIV).
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Social, political and environmental changes in the Congo Basin during this period suggest
that this account of the “Cut Hunter” hypothesis may oversimplify the drivers of zoonosis
[10, 14]. Transmission of the virus very likely involved blood-blood contact, due to the far
greater likelihood of successful infection, but butchering of primate meat is a much more
likely cause of transmission, not an incident during hunting itself. Today bush meat hunting
is still practiced and the butchering process is a source of many viral zoonoses [15-17]. The
abrupt economic retraction stemming from the Great Depression in the 1920s, not colonial
abuses, were the likely push to expand primate hunting, though not dramatically, which
had been practiced to some extent for at least 3,000 years [18]. By the 1920s these hunts
were likely safer than they had been in the past, as firearms were commonly used in
protection, warfare, and hunting since the mid-19th century [19]. Belgian rule over Congo
didn’t dramatically change firearm usage or ownership among rural African people, and
most historians conclude that the slow expansion and accumulation of modern weaponry
in Western and Central Africa remained steady through the late 19th and early 20th centuries
[20]. Additionally, intentional food shortages and extreme cruelty to the native Congolese
were curbed in 1908 after the transition from the Congo Free State, ostensibly privately
managed by Kind Leopold II, to the Belgian Congo. The new leadership, while still
oppressive, sought to improve the conditions of Congolese workers to curtail international
criticism of slavery and abuse.
These historical data, while sparse, suggest there is no force that accounts for a dramatic
increase in SIV exposure in the early 20th century that had not existed previously. The
changes in the Congo during this period were primarily in the movement of people, both
through forced relocations to work in the metal mines in the South and voluntary relocation
to major population centers [20]. Colonialism poured money into the resource-rich Congo
to rapidly develop huge plantations to produce rubber, palm oil and cotton while the South
was torn open for extensive copper mining. Thus, it is logical that humans have likely been
infrequently exposed to SIV for millennia, but widespread dissemination of these diseases
was limited. Forest societies in the region had always been mobile, but the construction of
extensive railway networks in the 1910s-20s allowed for greater transportation. Quickly
growing population centers like Kinshasa, a railroad hub that doubled in population
between 1920-1940, became focal points for viral transmission. While it would be easy to
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blame colonial cruelty as the root of the global HIV-1 pandemic, it’s likely that many
shifting environmental and social disturbances under colonialism, rather than the human
rights’ abuses, were the underlying drivers.

1.2.

Alternative Theories

Occasionally, researchers and conspiracy theorists have offered alternative theories about
the origins of HIV. Most pervasive among them is the theory put forward by Tom Curtis
in Rolling Stone magazine in 1992; contaminated plasma from an SIV infected chimpanzee
was used in developing the oral polio vaccine (OPV) in the Stanleyville region of the
Belgian Congo [21]. The vaccine was deployed to approximately a million Africans
between 1957-1960, an appealing theory to those who believe that a single infected
individual couldn’t be the origin of the pandemic. By exposing such a large population to
SIV, the theory states, it becomes much more likely to encounter an immunocompromised
individual who could support viral replication, regardless of how maladapted this virus was
to infecting humans. Despite the appeals of the contaminated polio vaccine theory, there is
no evidence of accidental or negligent infection of African populations with SIV/HIV due
to medical treatment. Employees at the facility in Stanleyville recall that chimpanzee
tissues were never cultured due to safety concerns, and that the vaccines administered in
the region were produced outside of Africa [22, 23]. These facts did little to dissuade those
who believed this theory and pushed researchers to identify the source of HIV-1 infections
in Africa.
The final blow to the contaminated OPV theory came in 2010. Published in Nature, work
from the groups of Drs. Beatrice Hahn and George Shaw conclusively demonstrated that,
while the Eastern chimpanzees (Pan troglodytes schweinfurthii) of the Stanleyville region
are endemically infected with SIV (SIVcpzPts), this strain does not resemble the SIVcpz
strain that led to the Group M epidemic (SIVcpzPtt, Central Chimpanzee, Figure 1.1), or
any transmissions establishing the HIV-1 or HIV-2 epidemics [24-28]. The geographic
isolation of the chimpanzee subspecies that harbor these different SIVcpz strains, about
800km between their ranges, makes it impossible for these subspecies to mix and there are
no known incidents of SIVcpzPts strains infecting either humans or any other primate
species [27, 28]. In later work, Hahn and Shaw demonstrated that the SIVcpzPts strain in
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the Eastern chimpanzees of the Stanleyville region cluster as an outgroup to SIVcpzPtt,
HIV-1 Group M and SIVgor [3]. This data conclusively identified SIVcpzPtt from Pan
troglodytes troglodytes chimpanzees from the Kinshasa region as the origins of both HIV1 Group M and N, as well as infecting gorillas to establish SIVgor which in turn later
transmitted to humans to found the Group O and P outbreaks. Finally, the timing of the
deployment of the oral polio vaccine in the late 1950s is several decades too late to coincide
with the origins of the Group M epidemic, situated around 1931 (95% confidence interval
between 1915-1941) [3-7]. The story of the cut hunter, while flexible in details, provides
the most realistic framework available to understand the origins of HIV group diversity.

1.3.

SIV Diversity and Pathogenesis

Distinct SIV strains infect over 40 different primate species and subspecies ranging
throughout Africa [29]. Most of these viruses are non-pathogenic in their hosts. For
example, Gorillas and sooty mangabeys in Africa, infected with SIVgor and SIVsmm
respectively, maintain high circulating viral loads but only rarely experience
immunodeficiency symptoms, and in those cases these symptoms manifest only in the
presence of exacerbating factors (e.g. advanced age or other infections) [30]. Loss of
virulence due to evolutionary attenuation has been observed in many viruses, though this
cannot be demonstrated experimentally in SIV [31-33]. Using genomic data from all SIV
lineages and models accounting for both host specific and independent molecular clocks,
the common ancestor of all SIVs is estimated to have existed between 2.5 and 5 million
years ago [34-36]. This loosely coincides with the diversification of the primate species
themselves, suggesting the virus and NHPs have coexisted through evolutionary time. It’s
important to note that in cases of cross infection with SIVs from other primate species, the
subsequent recombination has made estimates of SIV origin notoriously difficult and the
findings controversial [37].
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Figure 1.1) SIV origins of HIV infections with relative pathogenicity between groups.
Arrows denote transmission events between species, both between non-human primates
and, in the rightmost arrows, into humans in Central and Western Africa. The average
pathogenicity of each HIV variant can be ranked by the reported rates of CD4+ T-cell
depletion that they cause, illustrated on the far right [38-60]. Approximate numbers of HIV
infection denoted in parenthesis. Dashed lines denote groups with such small numbers of
infections that relative pathogenicity cannot be determined, only estimated.
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A small number of these SIVs can cause immunodeficiency when infecting a non-host
primate species, particularly Sooty mangabey SIVs infecting the three Asian macaque
species. The most common example of this is in the Asian primate Rhesus macaques,
which, when infected by SIVmac239 (a misnomer as this strain originated in Sooty
mangabeys) are the prototypic immunodeficiency model used by researchers globally [6163]. SIVmac239 infected macaques display many of the same markers of disease
progression as human immunodeficiency including the loss of CD4+ T-cells, loss of CD8+
T-cell function, degenerative changes in lymph node architecture, and neurological
symptoms. Much like HIV infections in humans, SIVmac infected macaques die from a
range opportunistic diseases [61, 62].
In the mid-1990s, researchers focused on identifying new SIV strains in reclusive monkey
species. By sequencing these new SIV strains, key discoveries were made regarding global
SIV diversity. Early phylogenies showed that each primate species’ SIV strain was
monophyletic, evolving with their primate host. However, more complete sequences of the
new SIV genomes showed that a few SIV strains thought to be evolutionarily distinct were
closely related and shared a recent common ancestor [63-66]. The assembled phylogenies
from these studies showed 5 groups of SIVs that displayed evidence of recent transmission
events between NHP species [29, 67]. The rest of the 40 known SIV strains are species
specific and it has been hypothesized that these viruses are adapted to their host species
and are non-transmissible [68, 69]. For example, SIV in the Sykes’ monkeys
(Cercopithecus albogularis) is phylogenetically unique and has never successfully
transmitted from its host species, despite regular interactions in the wild with other SIV
infected primates [70]. Monkeys that are preyed upon but do not hunt other primates
themselves, like the African green monkeys (Chlorocebus spp.), also harbor unique SIV
strains (SIVagm) that do not show evidence of recombination with other SIVs [65, 67].
SIVcpz, the ancestral source of the most pathogenic HIV-1 groups, M and N, diverges
significantly from the timeline of other SIVs [70]. Dating of SIVcpz divergence suggests
that chimpanzees acquired the virus long after diversifying from gorillas and bonobos, their
next closest primate relatives [4, 6]. This is especially likely due to the lack of SIV strains
infecting the Western and Nigerian/Cameroonian Chimpanzee subspecies, which diverged
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from the Eastern and Central Chimpanzee species during the last 500,000 years [35, 36].
Observations by the eminent primatologist/anthropologist Jane Goodall suggest that
hunting of other primate species by chimpanzees is the most likely source of SIV zoonotic
transmission [71, 72]. SIVcpz, when aligned to other closely related SIV strains, resembles
a mosaic of SIVs from Greater spot-nosed monkeys, Mustached monkeys, Mona monkeys
and Red-capped mangabeys, all prey species for Eastern and Central Chimpanzees [65, 67,
73] (Figure 1.1). Hunting as a mode of viral transmissions also agrees with the “missing”
SIV in Nigerian/Cameroonian Chimpanzee subspecies since they exclusively prey on
monkeys lacking SIV [74].
If SIV attenuated over time to become less pathogenic, then this more recent acquisition of
SIV correlates with the intermediate level of pathogenicity observed in naturally infected
chimpanzees relative to other SIVs. When infected, these apes display high viral loads and
some symptoms of immunodeficiency, including reduced numbers of circulating CD4+ Tcells and structural changes in their lymph nodes [24]. One key difference, however, is the
lack of AIDS-defining illnesses and opportunistic infection based-mortality in these
monkeys. Lifespan is significantly reduced but typically due thrombocytopenia leading to
heart failure, a comorbidity during SIV infection that is also occasionally observed in
chronically infected HIV patients.

1.4.

HIV Diversity

The most conservative estimates require at least twelve independent transmission events
of SIV into human populations of Africa, and very likely many more. The earliest
transmissions (1920-1930) led to the establishment of HIV-1 Groups M and N (from
SIVcpzPtt) and HIV-1 Group O (from SIVgor) [75-77]. Other HIVs appear to have arisen
from transmission events far more recently; HIV-2 (from SIVsmm in eight independent
events) likely transmitted in the 1960s and HIV-1 Group P and the SIV strain infecting
Western lowland gorillas (SIVgor) separating in approximately 1970 [6, 38, 78, 79] (Figure
1.1). The eight HIV-2 transmissions are geographically isolated from the rest of the SIV
transmissions, located much further northwest in Guinea-Bissau. A war for independence
in the region lasted from 1963-1974 against the Portuguese, displacing large numbers to
neighboring countries. It has been hypothesized that this abrupt displacement to larger
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population centers, much like in the Belgian Congo in the 1920s and 1930s, provided the
ideal environment for establishing a new HIV epidemic [6, 38, 79].
All forms of HIV lead to immunodeficiency, however they vary significantly in the rate at
which the disease they cause progresses (Figure 1.1). HIV-2 has been shown to cause a
very slowly progressing disease and has been typically geographically restricted to West
Africa due to poor transmission efficiency [39-41]. Those infected with HIV-2 generally
have very low viral loads, near the limit of detection, likely a major factor in the limited
transmissibility of these viruses [42]. This is especially evident in mother-to-child
transmissions, where ~30% of infants born to HIV-1-infected women become infected in
the absence of preventive interventions, while only about 1% of HIV-2-infected mothers
pass the virus to their infants [43-46]. Other studies in Western Africa have shown a
reduction in the time to AIDS when patients are infected with HIV-1 and 2 simultaneously
compared to HIV-1 alone [48]. The average time to the onset of AIDS in the absence of
treatment is about 8 years in a patient infected with a HIV-1 Group M subtype B virus [49].
In stark contrast, the same patient infected with an HIV-2 virus would reach clinical AIDS
in approximately 14-23 years [47].
Globally, HIV-2 makes up fewer than 5% of all HIV infections and has been declining
over the last decade, in contrast to HIV-1 that has increased dramatically in prevalence
over that same period. HIV-1 infections make up the remaining ~95% of global infections
and are approximately 55-75% divergent from HIV-2 at the nucleotide level [38, 39]. Very
small numbers of geographically isolated human infections by HIV-1 Groups N and P
viruses have been observed, each genetically differing from each other group by ~45% [5054]. Group M remains the only HIV group that has established epidemics outside of
Western Africa.
The diseases caused by non-Group M HIV-1 strains are more difficult to classify due to
the small numbers of infections documented relative to Group M. The most prevalent of
these groups is Group O, with almost a million documented infections since its
identification in Belgium in 1990 [55]. Almost all Group O infections are restricted to West
Africa, particularly Cameroon. The incidence of Group O infections has been steadily
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declining since its identification, even as the numbers of Group M infections continued to
rise in the same areas [56]. Group O disease largely mimics Group M infections though
with reduced rates of tropism switching and mother-to-child transmissions. There are also
increased numbers of elite controllers (patients who, without treatment, do not progress to
AIDS) and patients who develop broadly neutralizing antibodies as a result of Group O
infections relative to M [57, 58]. All of these factors likely contribute to a documented
slower progression to AIDS in Group O infections [59].
Group N and P infections are very rare, fewer than 20 Group N and 5 Group P infections
have been recorded. Perhaps due to this rarity these cases are closely documented, however
no concrete conclusions can be drawn about their disease progression. Case reports of
Group N virus infections resemble the disease caused by Group M. Mother-to-child Group
N transmissions have been documented, suggesting a far higher likelihood than other nonGroup M infections [51, 53]. Infections with Group N and M viruses typically require
phylogenetic testing in order to differentiate due to the similarity in disease at early
timepoints. Trajectories of CD4+ cell loss do not significantly differ between Group M and
N infections and many of the same comorbidities and AIDS-defining-illnesses have been
recorded [51-54, 75]. All of these measurements of disease progression are only available
for the ~20 patients with Group N infections and could easily be skewed by population and
selection biases. Group P, while capable of causing AIDS, appears to be the least
pathogenic of the HIV-1 groups [50]. However, it is important to note that the very small
numbers of infections make these conclusions impossible to validate [60].

1.5. Group M Diversity
The origins of HIV-1 Group M infections have been traced by Sharp and Hahn to a small
region of southeastern Cameroon within the Congo Basin [77]. Hahn and Sharp compared
SIV strains isolated from chimpanzee feces from across Central and Western Africa using
next-generation sequencing technologies [3, 25, 27, 28]. From this study they identified
the location of the SIV strain, that of the Central Chimpanzee, which most resembled HIV1 Group M, likely the location the virus established within a human host. While the first
decades of human transmission of HIV-1 Group M were sluggish, an epidemiological
threshold appears to have been passed in the 1950s that led to rapid increases in
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transmission [13, 80]. Hypotheses have been generated to explain this threshold, including
adaptation of the HIV-1 accessory genes nef and vpu [81]. The same epidemiological
threshold has not been reached by HIV-2 or other HIV-1 groups despite a similar early
trajectory. The increased transmission and global spread led to massive diversification
within Group M, yielding 9 viral subtypes: named A-D, F-H, J and K [82]. These subtypes
can differ by up to 35% of the nucleotide sequence and are heterogeneously distributed
globally [82-84]. Within each subtype, genetic variability is still quite significant, ranging
from 8-17%. Subtypes A and F each contain distinct variants, termed sub-subtypes, though
these variants differ enough to be considered unique subtypes by themselves (18-34%
nucleotide divergence). Subtype A is broken into sub-subtypes A1, A2, A3, A4 and A6
while subtype F is differentiated into sub-subtypes F1 and F2. Circulating recombinant
forms (CRFs) and unique recombinant forms (URFs) can also form when a single patient
is infected with multiple subtypes simultaneously, allowing the viral genome to recombine.
As of 2018 there are 96 identified CRFs in HIV-1 and one in HIV-2.
Conspicuously, HIV-1 Group M subtype nomenclature omits subtypes E and I. These
subtypes, referred to as “problematic”, were identified as distinct through incomplete
sequencing alignments [85]. When more complete sequencing was performed on the
samples, these subtypes were found to be recombinants including either subtype A or
numerous other Group M subtypes. For accuracy, subtype E was renamed circulating
recombinant form AE (CRF01_AE), while subtype I was renamed circulating recombinant
form complex (CRF04_cpx).

1.6. Group M Geographic Distribution
After crossing an epidemiological threshold in the 1950s, HIV-1 Group M diversified
greatly, primarily due to the very high mutation and replication rates coupled with large
numbers of newly infected individuals [76]. During this period the virus spread out of
Central and Western Africa. Dating the epidemic in South Africa suggests a subtype C
founder entered the population in approximately 1960 (+/- 8 years) [86]. Currently, South
Africa routinely has one of the highest HIV infection rates in the world and is almost
exclusively subtype C. Many published studies of the South African epidemic demonstrate
that the virus has spread much more rapidly in the same time period relative to Central
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Africa, where there is a greater diversity of circulating HIV subtypes circulating [86].
Recently, subtype C viruses have spread into China and India and appear poised to expand
further in many countries in Southeast Asia [87, 88].
Establishment of a subtype B virus from Central Africa in Haiti in ~1964 led to the first
epidemic in North America [89]. Sequencing of samples of known HIV+ individuals from
the mid-1970s demonstrated a clear link between Haiti subtype B viruses and the first
infection in the United States in New York City (dated to ~1970) [90-92]. In both Haiti and
the United States, the epidemic doubling time is placed at about one year (0.86-1.12)
suggesting extremely rapid expansion. The most likely theories about the arrival of HIV in
the Caribbean involve missionaries returning to Haiti from Congo in the 1960s and future
dissemination to Hispaniola, the Dominican Republic, and, eventually, the United States
[89]. There also exist many legends about the introduction of subtype B into the United
States and its early spread, typically involving a flight attendant patient zero, none of which
are substantiated by facts [93]. Following its introduction, subtype B quickly became the
dominant HIV subtype in not only North America and the Caribbean but also in South
America, Europe and Australia. HIV phylogenies show subtype B is a recent divergence,
likely pushed further by geographic evolutionary pressures and founder effects. This
recency manifests in the short branch distance between subtypes B and D, making them
the most closely related of the Group M subtypes, about 7% nucleotide distance in the pol
gene [80].
The predominance of subtype B in North America has led to a disproportionate focus in
research funding and efforts even though fewer than 11% of individuals living with HIV
globally harbor a subtype B virus [84]. The disease caused by subtype B provides almost
all estimates of “time to AIDS” used by clinicians worldwide, approximately 8 years in the
absence of treatment. This disease has been noted to be significantly more aggressive than
most other HIV groups and subtypes, but exactly to what degree remains controversial [94,
95]. Sub-Saharan Africa, the region with the greatest number of infected individuals, is the
source of all ancestral HIV diversity. While this region still contains the greatest viral
diversity, it is ironically generally devoid of subtype B infections, despite clear evidence
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of its origin in Kinshasa, Zaire [89]. This region currently primarily contains infections of
subtypes A, C and D [5, 96].

1.7.

Modern Epidemic and Research

In 1981, Acquired Immune Deficiency Syndrome (AIDS) was documented for the first
time. A series of patients presenting to hospitals across the United States displayed
opportunistic lung infections, particularly Pneumocystis carinii pneumonia, and highly
aggressive soft tissue cancer, Kaposi’s sarcoma, previously only seen in severely
immunocompromised individuals [97, 98]. Now, clinical AIDS is defined by the World
Health Organization (WHO) and the American Centers for Disease Control (CDC) as
either a CD4+ T-Cell count below 200 cells/mL in the circulation, a T-cell percentage of
total lymphocytes below 14%, or the presence of one or more of the 20 AIDS-definingillnesses. In order to validate the AIDS diagnosis, a patient must test positively for antiHIV antibodies, known as seroconversion [99].
In 1983 the etiological agent of AIDS was identified independently by Drs. Luc
Montagnier and Robert Gallo, a retrovirus originally branded the lymphadenopathy
associated virus (LAV by Montagnier) or human T-lymphotropic virus type 3 (HTLV-III
by Gallo), later renamed the human immunodeficiency virus (HIV) [100-102]. Prior to the
identification of HIV, no other lentivirus caused disease in humans. Identifying HIV as the
causative agent of AIDS finally provided a research target. Since 1983, 22 single drugs and
several multi-drug therapies have been approved by the U.S. Food and Drug
Administration (FDA), targeting multiple steps of the HIV replication cycle. New methods
of preventing infection have been developed including microbicides and pre-exposure
prophylactic drugs. Unfortunately, resistance mutations have been identified, at least in the
laboratory, to each of these drugs individually [103]. Two drug regimens targeting
independent steps in the replication cycle historically have been overwhelmed by HIV
mutation rates and develop resistance mutations to both drugs, though new combinations
may overcome this block [104]. For now, however, HIV positive patients’ regimens must
include three drugs to suppress viral replication and stem the development of drug
resistance.
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In the search of a cure, there have been four international vaccine efficacy trials which
administered Env protein based vaccines to thousands of people around the world [105].
Each of the first three trials failed, perhaps most spectacularly in the HVTN-502 study (or
“STEP study”) which increased the risk of infection in recipients. The final trial, RV144
or the “Thai trial”, combined lessons from each of the previously failed vaccines,
combining different Env immunogens to develop non-neutralizing and cellular immune
responses in its recipients. The results of the trial were promising, showing a 31% reduction
in the incidence of HIV in those vaccinated relative to controls [106]. Despite being the
most successful HIV vaccine trial, the efficacy remained too low for widespread
deployment and the results have been dissected and hotly debated, even before they were
fully released. While many researchers had concerns with funding allocation, some
epidemiologists raised significant concerns about selective patient exclusion during the
final analyses, which were necessary for statistical significance [107].

1.8.

HIV Genome, Viral Structure and Replication

The HIV genome is relatively small, even for viruses, at 10kb, varying slightly depending
on the viral strain (Figure 1.2A). Structural proteins are encoded by the gag gene on the 5’
end of the genome, enzymatic proteins encoded in the pol gene, while the env gene encodes
the structural Env protein, which is required for viral entry. Efficient viral protein
production requires the activator proteins Rev and Tat which promote transcription and
transport of mRNAs out of the nucleus. The remaining genes, vif, vpr, vpu, and nef are
grouped together and called accessory genes. None of the accessory genes have enzymatic
or structural functions, and most exist to antagonize cellular resistance factors.
The process of HIV infecting a susceptible and permissive cell are classified into distinct
steps: 1) attachment and entry, 2) reverse transcription, 3) integration, 4) transcription and
translation, 5) assembly and packaging, and 6) budding, release and maturation (Figure
1.3). Each of these steps are now targetable with different classes of antiretrovirals, though
resistance mutations have been identified to all developed drugs [103].
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Figure 1.2 A) HIV-1 Genome organization. Rows show reading frames with HXB2
nucleotide numbering shown below. Individual protein product abbreviations are denoted
below, gene names denoted above. Inset shows the env gene coding sequence with HXB2
nucleotide numbering. Variable regions and major features are labeled.
B) Assembled HIV-1 Virion Structure. The assembled viral particle consists of a Gag
matrix (MA) protein lattice with embedded env proteins (gp120 and gp41) protruding from
a host-derived membrane. The ribonucleic acid genome is contained within a Gag capsid
(CA) protein core. The interior of the viral core contains Protease, Tat, and Integrase with
Reverse Transcriptase (RT) and Nucelocapsid (NC) proteins in association with the RNA.
C) HIV-1 Env is comprised of a heterotrimer consisting of external gp120 and
transmembrane gp41 subunits. Gp120 contains a series of variable loops around its outer
surface and is heavily glycosylated. These variable regions interact with host cell proteins,
particularly the entry receptors CD4 and, in sexual transmissions, CCR5. Gp41 contains
two heptad repeats, a fusion peptide that inserts into the host cell membrane and a viral
membrane transmembrane region.
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1.8.1. Attachment and Entry
The first stage of HIV infection is viral entry, which comprises attachment, receptor and
coreceptor binding, membrane fusion and capsid/genome release into the cytoplasm. These
steps are mediated by the HIV Env glycoprotein, the only viral protein exposed on the
external surface of the virion. In order to evade the host immune system, Env is heavily
glycosylated and must undergo a series of conformational changes during the viral entry
process in order to expose the residues capable of binding and fusing with the host cell
[108].
The mature Env protein is heterotrimeric, consisting of three outer surface gp120 subunits
and three transmembrane gp41 subunits (Figure 1.2C). Gp120 is composed of a bridging
sheet linking an inner and outer domain. Notably, the inner domain contains both the N
and C-termini pointing inwards towards gp41 [109]. The inner domain consists of a 5
stranded β-sandwich and a two strand two helix bundle which are formed from the
conserved regions of gp120 (C1 to C5) [109, 110]. Five highly variable regions (V1 to V5)
extend outwards from the inner domain, making up the gp120 outer domain [111], forming
loops that interact with extracellular host cell proteins, and mediating conformational
changes and membrane fusion. The gp41 subunit is composed of a cytoplasmic tail, a
transmembrane region, a membrane proximal external region (MPER) and two
complementary heptad repeat regions (HR1 and HR2). These subunits, gp120 and gp41,
are translated together as a gp160 precursor and are subsequently proteolytically cleaved
at the cell surface. Following processing, noncovalent interactions are formed to hold these
glycoproteins together as heterodimeric subunits. Trimers of these subunits, also called
envelope spikes, are then reinternalized and trafficked to sites of viral assembly where they
bind structural Gag matrices.
The first interaction between a CD4+ T-cell and a viral particle involves non-specific
electrostatic interactions between the sugar residues of the HIV Env gp120 glycoprotein
with a number of host cell receptors, including the transmembrane receptor α4β7 Integrin
[112]. These nonspecific interactions concentrate the number of viral particles at the cell
surface, facilitating the interaction between the CD4 attachment receptor and the CD4
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binding site (CD4bs) of gp120 (Figure 1.3.1). This binding site is highly conserved and the
target of numerous identified neutralizing antibodies. Conservation at this site has also
rendered this an attractive candidate for drug design, however CD4 mimetics and other socalled attachment inhibitors have largely failed during clinical trials [113]. The only FDA
approved antiretroviral that prevents viral attachment is Enfuvirtide (EFV or T20),
marketed as Fuzeon. EFV has largely fallen out of regular use due to the rapid development
of drug resistance mutations in the virus [114].
Isothermal titration microcalorimetry has demonstrated that binding of the CD4 receptor
induces gross changes in both the exposed loops, including the V3 loop and the coreceptor
binding site, as well as within the protein core. These studies also suggest that before
binding to CD4, the viral envelope is capable of existing in multiple different
conformations, between open and closed, with roughly equal free energy [115]. Following
engagement with the CD4 receptor, the free energy of the system drops precipitously and
locks the Env protein into an open state. This state exposes more of the V3 loop and allows
the virus to bind its coreceptor (Figure 1.3.2). Although over fourteen different
transmembrane receptors have been shown to support HIV infection in CD4+ cell lines,
only CCR5 and CXCR4 have been shown to act as coreceptors in vivo [116-118].
Coreceptor binding initiates further conformational changes in the envelope, permitting the
insertion of the gp41 fusion peptide into the cellular membrane (Figure 1.3.3). Through
intermediate gp41 structural rearrangements, a fusion pore develops the viral and host cell
membranes mix (Figure 1.3.4). The capsid core structure, containing the viral genome, is
then able to pass through the fusion pore and into the cytoplasm of the cell.

Figure 1.3) The process of HIV entry into a target cell is divided into four main events: 1) attachment to a host cell via the CD4 receptor
engaging with the CD4bs of the HIV Env, 2) binding to a seven transmembrane chemokine coreceptor, typically CCR5 during sexual
transmission, 3) fusion peptide insertion into the host cell membrane, and finally, 4) fusion of the viral and cellular membranes.
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1.8.2. Reverse Transcription
The defining trait of retroviruses is the conversion of their single stranded RNA (ssRNA)
genome into a double-stranded DNA (dsDNA) viral genome via the process of reverse
transcription (Figure 1.4.3). The reverse transcriptase (RT) enzyme, encoded in the pol
gene, is a DNA polymerase with both RNA-dependent and DNA-dependent activities. RT
also has an associated ribonuclease H (RNaseH) with degradation activity of RNA in RNADNA duplexes. Reverse transcription occurs in the cytosol and requires an RNA primer to
initiate polymerization from the ssRNA genome template. In the case of HIV-1, a specific
host tRNA serves as this primer and binds to an 18 nucleotide region known as the primer
binding site (PBS) near the 5’ end of the genome (Figure 1.2A). This tRNA is incorporated
into budding virions and some primer extension occurs prior to viral entry [119].
Upon binding to the PBS, polymerization of minus (-) strand DNA proceeds towards the
5’ end of the genome. Digestion of the genomic RNA by RNaseH frees this short ssDNA,
known as minus strand strong stop DNA, which then hybridizes with the 3’ end of the
genome via a short repeat region of homology. DNA synthesis proceeds along the
remaining length of RNA genome in a 3’ to 5’ direction. RNase H leaves a region of RNA
in the env coding region known as the poly-purine tract (PPT). The PPT serves as a primer
for positive-strand DNA synthesis which proceeds in a 5’ to 3’ manner using the minusstrand DNA as template. A second strand transfer event occurs where the positive-strand
DNA binds to the minus-strand DNA at the PBS region which becomes present in both
DNAs. Second strand DNA synthesis completes through bidirectional synthesis by the
circular binding of the minus-strand to the positive-strand DNA. The double-stranded DNA
product of reverse transcription contains identical regions at the 5’ and 3’ ends termed the
long terminal repeats (LTR). These regions are essential for integration and mRNA
transcription and contain the enhancer, promoter, transcription initiation, transcription
termination and polyadenylation signals [120].

1.8.3. Integration
Following reverse transcription, the newly synthesized viral dsDNA must be imported into
the cell nucleus for integration into the host chromosome. This is accomplished through
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the formation of the pre-integration complex (PIC), a complex of host and viral proteins
that actively transport the dsDNA into the cell nucleus. The PIC consists of the HIV viral
dsDNA, the integrase (IN) enzyme, the viral Vpr protein, matrix protein, and host cellular
factors. Due to the size of the PIC complex, it cannot passively transfer from the cell
cytoplasm into the nucleus but must be actively carried into the nucleus through a nuclear
import pathway fueled by a RanGTP gradient (Figure 1.4.4 & 1.4.5). Nuclear localization
signals, found in matrix, vpr, and integrase, recruit nuclear importin proteins to the PIC.
This active nuclear transport process permits HIV infection of non-dividing cells such as
macrophages [121].
The process of integration initiates with a reaction known as 3’-end processing. The
integrase enzyme cleaves off two nucleotides from the 3’ ends of both strands of linear
viral DNA in a staggered manner, resulting in non-blunt ends. The 3’ recessed ends of viral
DNA bind with the cleaved cellular DNA in a strand transfer event. Integration is
completed when the gaps between the integrated viral DNA and cellular DNA are filled in
by cellular repair enzymes. Once integrated, the viral DNA is referred to as “proviral” DNA
[122].

1.8.4. Transcription and Translation
Following successful integration into the host chromosome, the proviral DNA is used as a
template for the synthesis of viral RNAs which encode the necessary structural, enzymatic,
and regulatory proteins for the production of progeny virus. The cellular machinery is
utilized for the transcription of viral RNAs, RNA-splicing, and nuclear export.
Basal transcriptional activity from the HIV LTR promoter is very poor. However, the Tat
protein is delivered to the entering virion and produced from a small number of RNA
transcripts generated early in infection [123]. Tat potentiates a positive feedback
mechanism promoting high level HIV mRNA transcription. Tat binds to a transactivation
response (TAR) element, a cis-acting RNA element that forms a stable stem-loop structure
located downstream of the transcription initiation site [124]. The Tat-TAR interaction
promotes the recruitment of a multicomponent kinase complex termed P-TEFb or positive
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transcriptional elongation factor b [125]. P-TEFb activates RNA polymerase II, promoting
processive mRNA elongation (Figure 1.4.6).
Three major groups of RNA transcription products are produced from the proviral DNA:
1) unspliced RNAs, 2) partially spliced mRNAs, and 3) multiply spliced mRNAs. The
unspliced RNAs serve as genomic RNA for packaging in progeny virions and encode the
Gag and Pol proteins. Partially spliced mRNAs encode the Env, Vif, Vpu and Vpr proteins
while short, multiply spliced mRNAs encode the Rev, Tat, and Nef proteins. Differential
splicing patterns can result in as many as thirty or more unique mRNA transcripts being
produced [126].
Most cellular mRNAs are fully spliced prior to leaving the nucleus. However, HIV
replication requires that partially and unspliced RNAs are transported out of the nucleus to
the cytoplasm. In order to overcome this dilemma, the Rev protein (regulator of expression
of viral proteins) binds to unspliced viral RNAs and shuttles them out of the nucleus. Rev
binds to a cis-acting RNA element known as the rev-response element (RRE) located in
the env gene. The RRE is a series of highly structured stem loops found in all unspliced
and partially spliced viral RNAs [127]. Multiple rev proteins bind to the RRE and form a
complex capable of interacting with the nuclear export machinery. Rev shuttles the
unspliced or partially spliced RNAs to the cytoplasm and return to the nucleus by way of
its nuclear localization signal. Once in the cytoplasm, viral protein synthesis from mRNA
transcripts ensues through normal cellular translational machinery.

1.8.5. Assembly and Packaging
Production of Gag and Pol proteins promotes assembly of new virus particles at the plasma
membrane. The matrix (MA) domain of Gag, which is located at the N-terminus of the p55
precursor protein, is cotranslationally modified by the addition of myristic acid. Mutational
studies suggest that a positively charged face of MA interacts with negatively charged
phospholipids of the plasma membrane, stabilizing membrane binding [128].
In addition to associating with the plasma membrane, Gag must also participate in GagGag and Gag-RNA interactions. The Gag-Gag interaction is thought to involve multiple
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regions of the precursor to form a matrix along the cell membrane [129]. In tandem,
interactions between NC and a cis-acting element located 5’ of the gag initiation site known
as the major packaging signal, or Ψ-site, mediate the incorporation of genomic RNA into
virus particles. The envelope precursor protein, gp160, is synthesized in the endoplasmic
reticulum (ER) and translocated into the ER lumen by means of an N-terminal signal
peptide comprised of approximately the first thirty amino acids of the polyprotein. In the
lumen, gp160 folds, disulfide bonds are formed, the protein is glycosylated, and
oligomerizes to form trimers. After gp160 is properly folded and trimerized, it is
transported to the Golgi complex where the polyprotein is cleaved by cellular proteases
into the gp120 and gp41 subunits. The gp41 subunit is anchored to membrane and
noncovalently associates with gp120. The envelope complex is trafficked to the plasma
membrane through the secretory pathway. Mutational studies indicate that the MA domain
of gag promotes envelope incorporation into budding virions through an interaction with
the cytosolic tail of gp41 [130].

1.8.6. Viral Budding, Release, and Maturation
Accumulation of Gag and associated RNA at the plasma membrane enhances the final
stage of virion assembly known as budding. A proline rich domain at the C-terminus of
Gag known as p6 encodes a small protein that promotes viral particle release from the
plasma membrane [131]. Multiple studies have indicated a connection between the
endosomal sorting pathway and the viral budding process. The observation that p6 interacts
with a component of the ESCRT-I complex (endosomal sorting complex required for
transport) further points to the importance of the endosomal sorting pathway in virion
release [132].
A cellular defense mechanism to prevent release and maturation of budded virus particles
involves a cellular factor, Tetherin, which physically tethers budding virus particles to the
cell membrane. These nascent particles are subject to internalization through endocytic
pathways. While it has been known for some time that the accessory protein Vpu promotes
release of virus particle [133], it has only recently been demonstrated that Vpu does so
through antagonization of Tetherin [134].
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Shortly after virus release from the membrane, the protease enzyme cleaves the Gag and
Pol precursors into the mature proteins. Once released, the structural proteins induce
rearrangements in the virion morphology in a process known as maturation. Mature virions
contain a conical shaped core encapsulating the RNA genome. Immature virions are not
capable of establishing productive infections and thus maturation is a requirement for
infectious particle production [135].

1.9.

HIV Disease

While modern medicine can reduce HIV replication to undetectable levels, in the absence
of treatment HIV+ people living with HIV undergo a predictable progression of disease.
Key features of the disease, such as the amount of infectious virus in the circulation (known
as viral load), transmission efficiency, time to the onset of AIDS, serious HIV-related
complications, and viral fitness, can be compared to quantify relative pathogenicity
between strains.

1.9.1. HIV Transmission
HIV transmissions between humans are classified into several possible routes: sexual
intercourse (both anal and vaginal for both partners), intravenous drug use (IVDU),
Mother-to-Child (MTC) during pregnancy or delivery, accidental inoculation with
contaminated bodily fluids (typically in health care workers) or during organ
transplantation [136]. The most prevalent pathway for transmission is sexual but other
modes may play a larger role in individual epidemics, like that of IVDU transmission in
the former Soviet republics [137, 138]. Regardless of route, transmitted virus undergoes an
immense genetic bottleneck, typically with a single viral variant causing infection in the
recipient [139-143]. In those rare instances in which more than one viral variant is
transmitted, patients experience a more rapid disease progression and reduced time to the
onset of AIDS. This bottleneck has significant consequences for viral replication, as the
transmitted-founder virus, or the virus establishing the new infection [144]. The most
apparent of these consequences is the near universal utilization of the CCR5 chemokine
coreceptor and reduced replicative fitness in the new host [145].
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Figure 1.4) The major steps of HIV replication: 1) Viral attachment to nonspecific extracellular receptors, 2) Specific viral interactions
with CD4 (red) and a chemokine receptor (typically CCR5 in green) that leads to release of the viral capsid into the cytoplasm, 3)
Reverse Transcription of the RNA viral genome into a DNA proviral genome, 4) Import of the pre-integration complex (PIC), 5)
Integration of the DNA provirus into the host genome, 6) Viral transcription and translation generating viral proteins and full length
RNA genomes, 7) Viral assembly at the cell surface, 8) Budding of the progeny virus and 9) Maturation into fully infectious new virions.
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Many transmissions of HIV occur during the early phases before symptoms are displayed
and without knowledge of the infected party’s status. Large scale testing efforts have been
implemented globally, but have limits since diagnosing HIV can be prone to challenges
and false-negative results [146, 147]. The long periods of asymptomatic infection during
HIV disease amplify these challenges and are responsible for the relatively poor rates of
HIV diagnosis. Of the 37 million people living with HIV, about 25% do not know that they
are infected [1]. These numbers are thought to be even higher in Eastern and Southern
Africa, the regions with the greatest HIV/AIDS burden.

1.9.2. Acute HIV Infection
The progression of HIV infection in the typical patient is classified into two phases, Acute
and Chronic, each with their own associated symptoms, CD4+ T-cell responses and viral
load dynamics. The Acute/Early phase, also called acute HIV infection (AHI), is classified
as the period between viral transmission and stable viremia following the viral set point.
Researchers frequently define the conclusion of this phase in terms of months postinfection, however the exact number of months can vary between 2 and 4 [148].
Immediately following transmission, within the first 2 weeks, the host innate immune
system is largely overwhelmed by the rapid replication rate of the virus and mutations that
evade host immune responses. Viral loads in the patient’s circulation can spike to 10 7
copies per mL and flu-like symptoms are common, however the precise symptoms vary
depending on the viral strain and host genetics [149, 150]. Typically, this fever is described
as resembling mononucleosis, with mainly minor symptoms including fatigue, headache
and swollen lymph nodes, though meningoencephalitis and other serious complications
have been observed [151]. Acute viremia can last up to several weeks before declining due
to the host adaptive immune system [152]. Seroconversion, or the detection of anti-HIV
antibodies in the patients’ circulation, typically occurs within the first 2 weeks following
infection [153]. Most antibodies produced during this disease phase have epitopes that
target the structural protein Gag and are non-neutralizing. Despite the inability to neutralize
virus, these antibodies are very important markers for disease progression and their titers
are one of the most reliable markers of pathogenesis [154]. The latent HIV reservoir, longlived memory T-cells containing integrated but not actively transcribed provirus, is also
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established within AHI. Even when antiretroviral therapy is implemented within 3 days of
virus exposure, the size and decay rate of the latent reservoir remains unaffected [155],
though its T-cell subset makeup shifts away from central memory populations and towards
resting memory T-cells [156, 157]. Both the size and makeup of the latent reservoir are
impacted by viral subtype and have significant implications for treatment, disease
progression, and long-term patient outcome [158-161].
Many clinical measurements during AHI have been associated with either slower or more
rapid disease progression. Peak viremia immediately following infection and viral load at
the set point have both been implicated as predictors of CD4+ T-cell loss [41, 162, 163].
Unfortunately, the reproducibility of these results is inconsistent and multiple other studies
have found no association between disease progression and AHI measurements,
particularly when compared across different viral and host populations [164, 165]. These
conflicts illustrate the difficulties predicting and evaluating disease progression in natural
cohorts due to patient and virus variability.

1.9.3. Chronic HIV Infection
Chronic HIV infection typically refers to HIV disease after AHI, or the period of disease
after the viral load set point. The set point represents an equilibrium between viral
replication and the host immune system. This post-set point disease is typically called the
asymptomatic phase of infection, which is marked by clinical latency of the disease. Viral
loads are reduced relative to the other phases of infection due to suppression by the host
innate and adaptive immune system. The asymptomatic phase of HIV disease progression
may not display any outward symptoms of infection, but many of the defining processes
of immunodeficiency occur during this phase [99]. Despite viral loads remaining low
during the initial months following AHI, viral fitness and diversity increase rapidly [29,
166, 167]. This is possible due to the sustained viral replication in lymphoid tissue even
during the asymptomatic phase of infection [168]. Viral replication is also sustained even
during ART [169-171], suggesting the viral replication and the symptoms of
immunodeficiency are not inextricably linked. This continued replication may be one of
the leading causes of drug resistance in patients who maintain high levels of drug
adherence.
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The asymptomatic phase of HIV infection is the longest phase of HIV disease. Since there
are typically few HIV-related symptoms, relatively few patients are aware that they have
been infected. Studies have shown that while both early and late stage HIV infections are
more transmissible, due to high circulating viral loads, most transmissions occur from a
patient in the asymptomatic phase due to the greatly expanded time scale [172]. The
asymptomatic phase typically lasts multiple years, even in the most aggressive of cases.
CD4+ T-cells are gradually depleted in a near linear rate over this period. Since these cells
are necessary for survival and proliferation signals to other immune cells, their depletion
leads to widespread immune system collapse, permitting opportunistic infections and rare
cancers with an associated infectious agent etiology to be observed. Most patients
experience one or several AIDS-related symptoms which include chronic wasting,
diarrhea, swollen lymph nodes, skin lesions or rashes, oral sores, neurological
complications, fatigue, fever and night sweats [173, 174]. The underlying driver of these
symptoms is the broad inflammation and immune activation perennially experienced by
HIV patients.

1.9.4. HIV Disease Cellular Biology
HIV disease has been characterized extensively over the decades following its emergence.
The virus is able to compromise the host immune system due to its capacity to infect and
deplete a number of immune cell types, primarily CD4+ or “helper" T-cells [175-178],
though the virus can also infect macrophages and dendritic cells, albeit less productively
[179]. The infection of CD4 T-cells eventually begins a multifaceted path to
immunodeficiency related to cell death of directly infected cells [180-182], bystander cell
apoptosis [183, 184], long-term immune activation [185-187] and impaired T-cell function
[188-190]. As the disease progresses, the CD4+ T-cell population is gradually depleted. It
has been documented that depletion occurs in particular T-cell subsets, namely the memory
populations, and T-cells with HIV specific T-cell receptors (TCRs) [191-193]. These
memory T-cells are a heterogeneous population of both effector memory and central
memory T-cells. Effector memory T-cells (CD45R0+/CCR7-) are more differentiated,
home to peripheral tissues, and can generate more effector memory cells in-vitro. Central
memory T-cells (CD45R0+/CCR7+) are able to self-renew and reside in primary lymphoid
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organs. Depletion of these populations is directly responsible for many of the characteristic
symptoms associated with HIV disease and AIDS.
The principal drivers of CD4+ T-cell loss in HIV patients has been subject to much
investigation, but many facets remain mysterious. Key discoveries in the field
demonstrated that the loss of CD4+ cells is centered in the lymphoid organs of the gut with
other local sites of replication including the lymph nodes [194]. Serving as a primary site
of viral replication, lymphoid organs undergo a progressive degradation of their structures
[168]. The lymphoid tissue degradation, as well as persistent inflammation, leads to the
characteristic “leaky gut” in chronically infected HIV patients [194]. Disruption of the
structure of the digestive tract leads to further inflammation and bacterial translocation into
the patient circulation, a vicious cycle that drives immune cell loss, particularly the cells
that are resident in the nearby lymphoid organs (Figure 1.5). Live animal imaging in
primate models has further validated lymphoid tissues as hotspots of viral replication, but
it is still unclear what molecular mechanisms push these infected cells towards death [195].
Recent discoveries have pointed towards infected cells undergoing pyroptosis, a caspase1 mediated, highly inflammatory form of cell death [196]. Other studies responding to this
discovery suggested apoptosis, T-cell mediated clearance and viral cytopathic effects as
the most important drivers of CD4+ T-cell loss [197, 198].
Bystander effects, or the death of uninfected, neighboring cells, has also been noted as a
primary cause of death in lymph nodes during HIV and SIV infections [199]. These
uninfected T-cells die via apoptosis, a caspase-3 mediated death pathway, that limits the
release of inflammatory signals. The rates of uninfected cells undergoing apoptosis remains
unaffected by the number of CD8+ T-cells, or cytotoxic T-lymphocytes (CTLs), suggesting
that the death is caused by signals released by nearby infected cells, namely inflammatory
cytokines [183]. During these same experiments, researchers also noted that productively
infected cells were not necessarily dying after producing virus. Instead, a balance between
latent and activated states causes these cells to persist [199]. These results suggest that the
depletion of CD4 T-cells during HIV disease has been largely misunderstood, and that CTL
responses and inflammatory cytokine signals drive the death of uninfected cells while the
cytopathic effects of HIV are minimal. CTLs induce apoptosis via the extrinsic pathway,
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typically via engagement of Fas, TNF or TRAIL with their cognate receptors, to actively
clear infected cells [200]. CTL response breadth, as well as the absence of CTL escape
mutations, have been identified numerous times as predictors of HIV disease severity and
the likelihood of viral control [201-205].
Finally, T-cells undergo a process of activation and expansion followed by contraction via
apoptosis in response to T-cell receptor (TCR) activation with their cognate antigen in the
context of MHC class II. HIV, being a highly inflammatory disease releasing huge amounts
of antigen, causes broad inflammatory responses throughout the body, activating immune
cells. The T-cells that activate in response will eventually undergo apoptosis or, in a
minority, will become long-lived, memory T-cells. The extent and intensity of chronic
immune activation strongly correlates with the timing of AIDS and CD4+ T-cell depletion
[185, 186, 194, 206].
Early experiments with HIV identified that these viruses require an activated cell to
replicate [207]. Access to chromatin is necessary for the integration process which is only
freed upon T-cell activation and active transcription. The long-lived memory T-cell
population has a lower threshold for activation, making these cells ideal targets for HIV
infection [208]. The effector memory subset (CD4+/CD45R0+/CCR7-) migrate to the
periphery of the infected patient, homing to sites of inflammation, and likely encountering
virus. Upon infection these memory cells can return to a quiescent state, forming the latent
reservoir of HIV [209, 210]. This reservoir is what renders HIV incurable, due to its rapid
formation after infection and the extremely long half-life of memory T-cells [171, 211].

1.9.5. Clinical Measurements of Disease Progression
HIV disease severity is typically quantified through a few clinical markers and diagnostic
tests. The most classic of these is viral load, or the number of viral particles in a patient’s
circulation, measured as copies per milliliter of blood. The test uses quantitative PCR to
measure the number of copies of the non-integrated HIV RNA genome that are present in
a sample. The development of this test was groundbreaking for its sensitivity in the
diagnosis of HIV infection and drug regimen effectiveness, detecting as few as 50 RNA
copies per mL of blood. Immediately clinicians and researchers identified both cumulative
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viral load, or viral load at the set point closely associates with the timing to the onset of
AIDS [41, 49, 160, 163, 212]. Recent investigations have identified many additional factors
which may skew viral load for patient prognosis in some rare instances, particularly when
concerning diverse HIV-1 isolates [160, 164].
Many host behavioral and genetic factors also exacerbate HIV disease progression. Stress,
mental illness, drug and alcohol use, sexual behaviors, vitamin deficiencies, co-infections,
rates of T-cell exhaustion, susceptibility to chronic inflammation, circulating cytokine
levels, and other viral and host genotypes have all been implicated in driving rapid disease
progression in different cohorts [163, 166, 213-236]. It is important to note, however, that
almost all of these factors have also been found not to have an impact on disease
progression in other cohorts/studies (e.g. alcohol and drug use in [237]). Many of these
associations are likely population specific and lack the human diversity in the study group
to properly control for host genotype.
Some host human leukocyte antigen (HLA) alleles, encoding for major histocompatibility
complex class I (MHC class 1) appear protective against HIV disease progression [238].
In particular HLA-B variants 57, 27 and 81 (HLA-B*57, HLA B*27 and HLA-B*81) are
commonly associated with stable CD4+ cell counts, slow disease progression, and lower
viral loads [239]. These alleles are non-homogenously spread across the globe. For
example, in Africa, HLA-B*57 is found frequently in some regions of Africa (e.g. Zambia
and South Africa) and at a low prevalence in other regions (e.g. Uganda and Zimbabwe)
[240]. In populations in which HIV is less prevalent, these HLA variants are likely selected
against due to their associations with many autoimmune disorders [241, 242].
Perhaps the most impactful host factor in determining HIV disease progression is the CCR5
gene itself. Discovered in 1996, a 32 base pair deletion creating a premature stop codon in
CCR5 generates a nonfunctional receptor that HIV is unable to bind to [243]. Since
engagement with a chemokine coreceptor is essential for HIV entry, individuals that are
homozygous for the Δ32 mutation are resistant to infection by CCR5-tropic viruses. Since
CCR5-tropic viruses make up nearly all transmitted viral strains, these individuals have
been documented to resist HIV infection even after repeated, high-risk exposures.
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However, rare instances have been observed in which CXCR4-tropic viruses can infect
Δ32 homozygotes [244]. Individuals who are heterozygous for the mutation, possessing
both full length and truncated versions of the CCR5 gene are semi-resistant to HIV
infection, with reductions in infection rates near 50%. Researchers soon identified the
mechanism of this partial inhibition; due to the required dimerization of CCR5 receptors
while being transported to the cell surface. A truncated copy of the CCR5 receptor is unable
to dimerize, thus greatly reducing cell surface CCR5, rendering the T-cells in these patients
largely non-permissive [245]. Additionally, upon infection, heterozygotes progress to
AIDS more slowly, delaying its onset by about 2-3 years relative to homozygous wildtype
CCR5 patients [246, 247].
While the Δ32 mutation is highly advantageous in preventing or limiting HIV infection, it
remains a relatively rare allele. Depending on ethnicity, heterozygotes make up about 10%
of the population in Europe, the continent with the highest frequency (about 1%
homozygotes). This rate varies depending on ethnic background within Europe, with the
highest levels of the mutation identified in people of Finnish descent (16% heterozygotes)
and the lowest in Sardinian people (4% heterozygotes) [248]. All other continents have
significantly lower rates of the mutation. The origins of the Δ32 mutation are hotly debated
but appear to be recent and linked to reductions in pathogenicity of other human diseases,
namely the bubonic plague (Yersinia pestis) or smallpox [249]. Conversely, individuals
with Δ32 mutations also appear to be at greater risk of infection or mortality from
flaviviruses, demonstrating the positive and negative selection dynamics on this allele [250,
251].

Figure 1.5) Summary of HIV Pathogenesis. Red lines represent CD4 T-cell counts per mL of blood in the circulation (solid red) and
CD4 T-cell density in the lymphoid tissues (dashed line) over the course of infection. HIV viral load (black solid line) is also shown in
infectious units per mL of blood (limit of detection at about 102 infectious units) with major disease features labelled.
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1.10.

Group M Subtype Pathogenesis

Infections by different HIV Group M subtypes have long been considered to differ in
pathogenicity, however exactly why and to what degree remains poorly understood. A
series of epidemiological studies report differing patterns in the rates of disease progression
and disease severity across Group M subtypes [252-258]. Unfortunately, the patterns
suggested by each study directly contradict others, and seem to be swamped by
confounding variables, poor controls, and conclusions that are not adequately supported by
the data.
The laboratory of Dr. Eric Arts has published direct comparisons of the relative replicative
fitness via primary viral competition assays across all Group M subtypes (Figure 1.6) as
well as between Groups M, N, O and HIV-2 (Figure 1.7) [255, 256]. Replicative fitness, in
this sense, refers to a virus’s ability to replicate in a given environment. During these
competitions, a single culture of primary activated CD4+ cells is infected with equal
amounts of two viruses of differing groups or subtypes. These infections progress through
multiple rounds of replication before viral nucleic acid is isolated and sequenced using
high-throughput, next-generation sequencing (NGS) technology [255-257]. These data
demonstrate the greatly reduced (up to 1,000 fold) replicative fitness of subtype C relative
to subtypes A, B and D (Figure 1.6C).
Intragroup competitions also show that subtype C clones more closely cluster with HIV-2
isolates than with other Group M subtypes (Figure 1.7D). The well characterized reduction
in pathogenic capacity of HIV-2 viruses strongly suggests similarly slow rates of disease
progression during subtype C infections [39-41]. It has also been observed in subtype B
infections that a greater proportion of untreated, infected individuals that do not progress
to AIDS (Elite controllers) are infected with less fit viruses [259, 260]. These data highlight
the direct effect of viral replicative fitness on patient disease progression and outcome.
Elite controllers have also been found to harbor viruses with envelope proteins that interact
with their cell surface receptors with low affinity and therefore infect cells with greatly
reduced efficiency [261]. These results demonstrate a direct link between viral entry
kinetics, fitness and viral suppression. However, these studies are unequipped to associate
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reductions in viral fitness with pathogenicity and rates of disease progression in non-elite
controlling patients.
While uncommon, a few experimental explorations of HIV-1 Group M subtype
pathogenicity have been previously published. The earliest of these investigations suffered
from errors of convenience recruiting all HIV+ patients available in a given study site [94].
These recruitment tactics were typically recognized as less than ideal but were necessary
to generate the statistical power necessary to tease apart an interaction as complex as
immune system failure and HIV disease progression. The flaw in this study design is based
around calculations of the time of infection based on clinical measurements like viral load
and CD4+ cell counts. The variability due to host and environmental factors makes these
estimates heavily biased, far outweighing any subtler effects of viral genotype.
Other studies, while properly controlling for date of infection, failed to generate the
necessary statistical power for robust analyses. In a study published in the Journal of
Infectious Disease in 1999, Kanki et al. recruited all registered sex workers in Dakar,
Senegal for biannual HIV monitoring (study ran from 1985-1997). Of the nearly 2000
women enrolled in the study, 81 seroconverted during the study period and 11 of those
reached clinical AIDS, defined as CD4 T-Cell counts below 200/mL. The study concluded
that subtype C displayed a rapid disease progression simply because 3 of the 4 enrolled
patients infected with subtype C viruses reached clinical AIDS during follow-up, their only
measure of disease progression. Subtype A, the most represented subtype among
seroconverters in the study, showed an eight-fold decrease in the likelihood of reaching
clinical AIDS relative to non-A subtypes. This finding was soon refuted by multiple studies
in Europe and Thailand showing either no difference in disease progression between
subtypes or increased rates of pathogenesis in subtypes A and CRF01_AE relative to
subtype B. Most recently, analyses in the Rakai cohort in rural Uganda demonstrated rapid
disease progression in patients infected with subtype D relative to all other subtypes in the
region. The rapid disease progression by subtypes B and D are the most pronounced and
frequently reported, while subtypes A and C are typically considered less aggressive. These
findings, like most studies quantifying disease progression, are still actively debated [94].
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1.11.

Thesis Overview and Rationale

1.11.1. Chapter 2 – Infecting HIV-1 Subtype Predicts Disease
Progression in Women of Sub-Saharan Africa
The broader HIV diversity, that is comparisons between HIV-1 and 2 and between the
groups of HIV-1, has clear implications in disease progression. This differential
pathogenicity has largely relegated non-HIV-1 Group M infections to small regions of
Africa and limited the numbers of transmissions. What is unclear however, is whether the
genetic diversity within Group M confers a similar range of disease progressions, what that
pattern is, and how it impacts the cellular replicative cycle of HIV. Previous work has
shown that this diversity manifests in a distinct pattern of replicative fitness in which
subtype D and A outcompete subtype C in activated PBMCs. While low replicative fitness
has been linked to viral control, there are no published direct measurements of the rate of
CD4+ T-cell loss between multiple Group M subtypes in a single human population.
Herein we seek to explore the role of HIV-1 Group M diversity on the diseases they cause,
whether there is a continued link to viral replicative fitness, and whether the association
with viral attachment and cellular entry hold when modelling CD4+ T-cell declines. In
response to other published work we will also investigate viral load dynamics over the
study period, specifically how diversity may impact circulating viral levels in both acute
and chronic phases of disease.
Cellular entry, the first stage of viral replication, is most closely linked with replicative
fitness, but has not been directly implicated in severity of HIV disease. We will use three
novel assays to interrogate viral rates of cell entry, affinity for the CD4 receptor, and
induction of multi-cell fusion.
Despite decades of research, the diversity of HIV-1 Group M around the world is rarely
considered. Viruses of subtype B from North America makes up nearly all published work.
Subtype diversity clearly will impact cure strategies, testing efforts, antiretroviral
prioritization and will direct future spread of the pandemic.
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1.11.2. Chapter 3 - HIV-1 Group M subtypes deplete memory and
naive T-cell populations at different rates
Previous investigations into CD4+ T-cell decline will be expanded to interrogate the
dynamics of specific subsets with a focus on long-lived memory populations. Flow
cytometry separations of archived cohort samples will be used to measure CD4+ and CD8+
T-cell dynamics, as well as CD8+ cell patterns of activation. These memory populations,
when infected, allow for HIV to outlast even the best treatment regimens and rapidly
rebound upon cessation. The role of HIV-1 Group M diversity on memory T-cell depletion
has not been explored and will be a key determinant in the success of future cure efforts.
These analyses seek to identify T-cell populations that are differentially depleted between
subtypes, highlighting the differences in pathogenicity identified in Chapter 2.
Finally, in response to other published work, we will examine different measurements of
pathogenicity, that is time to unenrollment from the cohort as a proxy for the time to clinical
AIDS. This methodology has been utilized previously in reporting contradictory findings
to our own. We will use a Kaplan Meier estimator to track unenrollment based on infecting
HIV-1 Group M subtype and statistically compare between groups.
The future of HIV research will be disproportionately focused on memory T-cell subsets.
These populations harbor integrated provirus for decades, evading combined antiretroviral
therapy (cART). If they are to be eradicated, it is critical to understand the scope of the
global challenge. Most measurements of memory subsets only focus on subtype B viruses
while we will use a diverse group of viruses from Uganda and Zimbabwe to compare
pathogenicity.
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Figure 1.6) Ex vivo replicative fitness derived from pairwise competitions between HIV
Group M subtypes (A) Each CCR5 tropic primary isolate was competed against all of the
other CCR5 tropic isolates. (B) Each CXCR4 tropic isolate was competed against all of the
other CXCR4 tropic isolates. Fitness differences for the pairwise competitions were
determined based on relative quantities of viral nucleic acid isolated post competition.
Green boxes represent competitions in which subtype C was outcompeted by a non-subtype
C isolate while Red boxes represent subtype C outcompeting non-subtype C isolates. (C)
Results from the above matrices plotted by a given isolates replicative fitness calculated
from all competitions. The lower left quadrant represents the least fit viruses while the
upper right quadrant represents the most fit. Figure adapted with permission from [255].
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Figure 1.7) Mean relative fitness values (0=less fit, 2=more fit) for intratype/intragroup
and intertype/intergroup competitions in PBMCs involving both CCR5 and CXCR4 tropic
(A) HIV-1 group M, (B) group O and (C) HIV-2 primary isolates. (D) Intertype/intergroup
versus intratype/intragroup mean relative fitness of all CCR5 isolates. Clustering
represents viruses of similar fitness, with the most fit viruses in the top right quadrant and
the least fit viruses in the lower left quadrant. Figure adapted with permission from [256].
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Chapter 2
Infecting HIV-1 Subtype Predicts Disease Progression
in Women of Sub-Saharan Africa
2.1 Background
Human immunodeficiency virus type 1 emerged in the human population from the Congo
River basin shortly after the turn of the 19th century following an established zoonotic
jump of simian immunodeficiency virus from Pan troglodytes troglodytes [1]. Sixty to
seventy years of deforestation, exploitation, and urbanization likely led to evolution,
adaptation, and prevalence of HIV in the human host as well as the eventual spread of HIV
across Africa [2]. Distribution of HIV-1 across the globe over the past 30-35 years can still
be traced to founder events with primordial HIV strains from sub-Saharan Africa [1-3].
Our knowledge of HIV-1 disease and treatment is still largely limited to the 3 million
subtype B HIV-1 infections that dominate North America and Europe despite the mixture
of HIV-1 subtype A, C, D, and circulating and unique recombinant forms (CRFs and URFs)
responsible for 30 million historic and 28 million current infections in sub-Saharan Africa
[1-3].
The extreme genetic diversity between HIV-1 subtypes has phenotypic consequences in
vitro including differential HIV-1 mRNA transcriptional control [4, 5], protease activity
[6], integration site selection [7], MHC class I downregulation [8], and entry efficiency [9].
Overall, subtype C HIV-1 isolates display a significant reduction in replicative fitness in
primary human CD4+ T-cells relative to HIV-1 isolates of any other subtype [10-12].
Despite these studies, comprehensive analyses on the natural history of non-subtype B HIV
infections are still not available to guide treatment and prevention strategies in the >28
million people currently living with HIV-1 in sub-Saharan Africa. A few longitudinal and
cross-sectional studies on patients in sub-Saharan Africa have suggested that subtype A,
C, D and URFs/CRFs HIV-1 infections could have different disease courses and treatment
outcomes as compared to subtype B infected populations [13-19]. Faster progression to
AIDS and higher treatment failures were observed in subtype D versus subtype A
infections [15, 16, 20].
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From 1999-2003, over 4,400 HIV-negative women in Uganda and Zimbabwe were
enrolled in the Hormonal Contraception and the Risk of HIV Acquisition (HC-HIV) Study
[21], during which 303 women were identified with incident HIV infection and participated
in the Hormonal Contraception and HIV-1 Genital Shedding and Disease Progression
among Women with Primary HIV Infection (GS) Study [22-24]. The 76 subtype A, 177
subtype C, 31 subtype D and two URF HIV infected women (286 of 303 women) were
followed for an average of 5 years, currently the largest natural history cohort of nonsubtype B infections. Consistent with WHO recommendations at the time of the study,
treatment was provided when HIV-infected participants reached CD4 cell counts below
200/ml on two consecutive tests or were diagnosed with stage IV or advanced III disease
(WHO Classification). Antiretroviral therapy (ART) was not yet routinely available in
these countries during the study period, however, the study team felt that it was ethically
imperative to provide treatment to women participating in the project and committed study
resources to provide that treatment. This study was designed to monitor immunologic and
virologic parameters and to compare these biomarkers of disease progression to country of
origin, contraceptive use, infecting subtype, and phenotypic properties of the virus.

2.2 Methods
2.2.1 Participants and clinical tests
A complete description of the Ugandan and Zimbabwean participants is provided in the
Supplementary methods and previously described [23, 24]. Women who became HIV
infected while participating in the Hormonal Contraception and Risk of HIV Acquisition
Study in Uganda and Zimbabwe [21] were enrolled upon primary HIV-1 infection into a
subsequent study, the Hormonal Contraception and HIV-1 Genital Shedding and Disease
Progression among Women with Primary HIV Infection (GS) Study [22-24]. Blood and
cervical samples were collected every month for the first six months, then every three
months for the first two years, and then every six months up to 9.5 years. Women who had
CD4 lymphocyte counts of 200 cells/ml and/or who developed severe symptoms of HIV
infection (WHO clinical stage IV or advanced stage III disease) were offered combination
ART (cART) and trimethoprim-sulfamethoxazole (for prophylaxis against bacterial
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infections and Pneumocystis jeroveci pneumonia). In addition, information was collected
at every visit related to changes in sociodemographic information, sexual behavior,
sexually transmitted and reproductive tract infections, opportunistic infections, and diet.
Following primary infection, 112 Uganda and 174 Zimbabwean women were followed for
an average 1,826 and 1,899 days (respectively) (Supplementary Figure 2.1) for a maximum
of 3,453 days (9 ½ years) (Supplementary Figure 2.1). Antiretroviral treatment was
initiated in 23% of the women in both countries but 100 days sooner on average in the
Ugandan versus Zimbabwean women (1,458 versus 1,558 days) (Supplementary Figure
2.1). As described [22], cervical and plasma viral loads were determined with the Roche
Amplicor HIV-1 Monitor Test, version 1.5 using cryopreserved samples from visits from
every three months. CD4 T-lymphocyte counts were determined by standard flow
cytometry using FACSCalibur (Becton Dickinson, Sparks, MD, USA).

2.2.2 Models to determine viral load increases and CD4 cell
declines.
A marginal model with the generalized estimating equation (GEE) approach including
autoregressive error structures (accounting for repeated measurements on the same
individual) was used to determine the plasma viral load changes and compare rates of CD4
cell decline [22]. Multivariable analyses included demographic, sexual, contraceptive and
medical history data and underwent stepwise model simplification with a significance
threshold of p≤0.05. All analyses used Stata Version 14 (StataCorp LP, College Station,
TX).

2.2.3 DNA sequencing and subtyping.
DNA was extracted from patient PBMC samples obtained at the seroconversion visit and
every 3 months post HIV infection. Primers specific to the protease (PR) and polymerase
regions of reverse transcriptase (RT), and C2-V3 envelope (env) coding regions were used
to PCR 300, 800, and 450 nt regions as described [12] in a Virology Quality Assurance
(VQA) certified laboratory in Kampala, Uganda [22]. The HIV-1 sequences were edited
using BioEdit v7.0.4 and PR-RT coding regions were uploaded into the Stanford
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University HIV Drug resistance database (http://hivdb.stanford.edu) to obtain drug
resistance profiles. Phylogenetic alignments were performed using maximum likelihood
methods (MUSCLE [25]) and trees constructed using SEAVIEW 4 [26] and FigTree 1.4
(http://tree.bio.ed.ac.uk/software/figtree/). Each participant PR, RT, and Env sequence was
aligned to curated set of subtype A, B, C, D, G, and CRFs HIV-1 reference sequences
(hiv.lanl.gov).

2.2.4 Virus cloning and propagation
The entire gp120 coding region and the extracellular domain of gp41 (referred to as Env
DNA) was PCR amplified with the ENV REC primer set from PBMC DNA derived from
the patient samples at the seroconversion visit. Briefly, pREC_nflΔenv/URA3 was
linearized with SacII (Fermentas) and transformed into Saccharomyces cerevisiae MYA906 cells (ATCC) using lithium acetate along with Env PCR products [27]. Following
homologous recombination, plasmids were extracted from the yeast cells growing on plates
containing minimal media, 5-Fluoroorotic Acid (5-FOA) but lacking leucine. The yeast
derived plasmid DNA was then transformed into electrocompetent Escherichia coli Stbl4
cells (Invitrogen) and amplified for high purity plasmid purification using the Qiagen
midiprep kits. Detailed procedures of the yeast recombination/gap repair for HIV-1
cloning has been described [27]. The resulting pREC_nfl plasmid contains a subtype B
NL4-3 backbone with the patient derived gp120/gp41 ecto coding region. This plasmid
produces virus-like particles and can be used to access Env glycoprotein function and to
measure the rate of host cell entry in virus [28] and cell-to-cell infections [29]. pREC_nfl
(containing the patient derived Env gene) can also be co-transfected with pCMV_cplt
complementing vector in 293T cells to produce replication-competent virus as describe and
used for the studies on replicative fitness [27].

2.2.5 Reverse Transcriptase Assay
To quantify viral particles, we utilized a previously published radioactive nucleotide
incorporation assay to measure viral reverse transcriptase [262, 263]. Briefly, 10μL viral
concentrates were added to a 96 well plate. 25μL RT buffer was added to each well of the
plate (50 mM Tris-HCl (pH 7.8), 75 mM KCl, 2 mM DTT, 5 mM MgCl 2, 5 μg of poly(rA)
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per ml, 0.5% NP-40) and allowed to incubate for 10 minutes at room temperature. 1μL
radiolabeled thymidine triphosphate is then added (10-mCi/ml [α-32P] TTP). Plates were
then incubated at 37°C for 2 hours. The synthesized radioactive DNA is then blotted onto
DEAE filter mats (Wallac) and dried on a hotplate. The mats are then washed in SSC buffer
(x5) and 85% Ethanol (x2) and dried again to remove unbound radiation. Finally, these
radioactive mats are placed in plastic bags and exposed on a cassette which are read on a
Phosphimager (GE Storm 840). Quantification of radioactive spot intensity was done using
ImageJ. A more detailed protocol is available in previous publications [262, 263].

2.2.6 Replicative fitness
47 primary HIV-1 isolates of subtypes A (12), C (27), and D (8) derived from patients from
cohorts from Europe, South America, Asia, and all regions of Africa were titered on PHAactivated, IL2-treated PBMCs of HIV-negative donors using the standard Reed-Munch
TCID50 determination [30] then competed against 25 subtype B HIV-1 in the same
PBMCs. We also competed two reference subtype B HIV-1 isolates, B-QO and B-K44
against chimeric viruses derived from the acute/early infection samples of 5 subtype A, 3
subtype D, and 5 subtype C infections of this cohort. The relative production of two viruses
in each competition was measured by a radiolabeled heteroduplex tracking assays or using
next generation sequencing [10-12]. Assay sensitivity is 100-fold differences in replicative
fitness expressed as percentages.

2.2.7 Cell-to-cell infections
Veritrop involved the transfection (Fugene 6, Promega) of the pRECnfl constructs
containing patient Envs into 6.5x104 HEK293T cells [29] then cultured for 8 hours. To
synchronize Env engagement and cell fusion, the effector HEK293T cells were placed on
ice before being spun onto 6.5x104 of U87 CD4+ CCR5+ target cells (500 x g for 5 minutes
at 4°) transfected with a HIV tat-responsive luciferase plasmid (pDM128fluc). Co-cultures
were then brought to 37°C and allowed to form syncytia for 12 hours. Fully inhibitory
concentrations of Enfuvirtide (3uM) were added at discrete time points (t=4, 4.75. 5.5, 6.25
and 7 hours post combination) to replicates of each construct throughout this incubation to
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stop fusion events. Medium was removed after 12 hours and the Bright-Glo Luciferase
Assay System (Promega) was used to quantify luciferase production on a plate reader
(Biotek Synergy 2). Drug treated cells were compared to untreated controls to calculate
percent maximal fusion. Relative rates of fusion by Env subtype were statistically
compared based on time required to reach 50% maximal fusion (ANOVA, STATA Version
14, College Station, TX).

2.2.8 Virus entry into host cells
Cotransfection (Fugene 6, Promega) of the pMM310 plasmid (NIH AIDS Repository, cat
#11444) with the pRECnfl patient constructs into 3.0x105 HEK293T producer cells
generated viruses containing the HIV-1 accessory protein Vpr fused to E. coli β-lactamase
(BlaM). The viruses were purified via ultracentrifugation and quantified using p24 ELISA
(NCI Frederick Cancer Research and Development Center, AIDS Vaccine Program).
1.5x104 U87-CD4-CCR5 cells were plated on black, clear-bottom plates and loaded with
CCF2-AM dye (Live-BLAzer, ThermoFisher) for 60 minutes. The pRECnfl/BlaM viruses
were added to the culture at a multiplicity of infection of 2. Cells were placed on a plate
reader (Synergy 2, Bio-Tek) and virus entry was quantified every 15 minutes by comparing
emission at 460nm (cleaved dye) relative to emission at 530nm (uncleaved dye) following
excitation with a 405nm laser. Dye cleavage curves were normalized relative to cell-free
and virus-free controls, means calculated for each subtype and statistically compared based
on time required to reach 75% maximal viral entry (ANOVA, STATA Version 14, College
Station).

2.2.9 Competitive CD4 ELISA
96-well plates were coated with Goat Anti-Human IgG Fc Ab 1:10,000 and 100µL was
added per well. These plates coated overnight at 4°C. Following the incubation, the plates
were washed three times with 0.05% Tween-20 (Sigma) in DPBS. 100µL of 10% FBS in
DPBS was added to the plates to block and they were incubated at room temperature for 1
hour. Washes were repeated. 100µL of IgG-anti-Fc antibodies at 0.2 μg/mL in DPBS were
added to each well and incubated at room temperature for 1 hour. Washes were repeated.
Blocking steps were repeated for 1 hour at room temperature. 100µL of CD4-Fc fusion
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protein diluted in DPBS was added (20μg/mL) to all wells, followed by repeating wash
steps. 50µl of purified virus was added in triplicate for 5 timepoints, 15 wells per sample.
Plates were then sealed with plate seals and incubated overnight at 4°C. Following the
incubation, wash steps were repeated. 100µL of soluble CD4 (sCD4) diluted in DPBS was
added (20μg/mL) to all but the non-competed controls which received 100µL DPBS.
Competitions incubated at 37°C for 4, 12, 24, and 48-hours post-addition of sCD4. Wells
were washed with plain DPBS to remove unadhered virus and filled with 100µL DPBS to
prevent desiccation. Once all competitions finished the DPBS was aspirated and each well
received 25µL of lysis buffer and the quantitative reverse transcriptase assay was employed
to measure remaining bound virus. Results from a subsample of these trials are shown in
Supplementary Figure 2.6. To conserve reagents, future experiments would only use the
24-hour timepoint, where differences between subtypes was found to be most pronounced.
Comparisons between subtypes were made with ANOVA using Tukey multiple
comparison tests, significance p<0.05. Schematic of the assay is shown in Figure 2.6A.

2.3 Results
2.3.1 Monitoring disease progression in the absence of
treatment
Newly infected Ugandan (N=112) and Zimbabwean (N=174) women, 71% (N=203)
enrolled within 18 weeks of the infection date were followed for an average of 5.1 years
up to 9.5 years in the absence of combination antiretroviral therapy (cART), initiated when
CD4 cell counts dropped below 200/mm3 or concurrent counts below 300/mm3
(Supplementary Figure 2.1). Complete sociodemographic, clinical chemistries, and other
clinical data has been reported [22-24, 31].
Lower CD4 T-cell levels were reported in uninfected women and in our early infection
cohort of Zimbabwean women as compared to Ugandan women [31]. Despite this
difference between countries, declines in CD4 T-cells was 2-fold slower in the
Zimbabwean women population than in the Ugandan women in the absence of treatment
(Figure 2.1a&b) (GEE model; P<0.001).

Figure 2.1) The graphs around the map display the number of people living with HIV-1 between 1980 and¬¬ 2015 in the four UNAIDS
Regions with the greatest number of infections as well as globally. The distribution of subtypes in 1990 and 2015 are shown in the inset
pie graphs, scaled by the number of infections. Relative numbers of subtype C infections per UNAIDS Region are reported on the pie
graphs and via red shading on the map. Data compiled from the World Health Organization, UNAIDS and published literature
(References in Supplementary Files).
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Virus levels at both the set point and all future time points in the plasma and endocervix
did not significantly differ by country (Figure 2.2a) [22]. The cohort was also analyzed for
rapid progressors (CD4 decline to below 200 cells/ml within 2 years of infection) and
controllers/non-progressors (stable CD4 cell counts above 350 with viral loads <2000
copies/ml in plasma for more than 3 years post-infection) in the absence of treatment.
Approximately 7.4% (n=13) and 8.1% (n=9) were classified as rapid progressors in
Zimbabwe and Uganda but controllers were observed in less than 3% (n=3) of Ugandan
women versus 10% (n=18) of Zimbabwean women (Figure 2.1d). When rapid progressors
and controllers were removed from the analyses, the CD4 declines were still significantly
slower in Zimbabwean versus Ugandan women (P<0.001). As reported by numerous
studies, the rate of CD4 decline is directly associated with HIV disease progression [1, 3].

2.3.2 Possible factors contributing to country-specific difference
in disease progression
To explain these differences in CD4 T-cell decline between countries, we analyzed
numerous factors previously described as correlates of disease progression. Opportunistic
infections and secondary infections (malaria, TB, various STIs) were not significantly
different in the cohorts and each infection was treated accordingly upon diagnosis. Other
factors such as diet, recurrent sexually transmitted diseases (chlamydia, trichomonas,
HSV-2, bacterial vaginosis), smoking, sexual behavior, depomedroxyprogesterone acetate
(DMPA) use, and combined oral contraceptives (COC) use did not show significant
differences in HIV-1 disease progression between countries [22-24, 31, 32]. There may be
a perceived difference in human genetics between the two countries that may explain this
differential disease progression. Our informed consent and institutional review board
(IRB) approvals did not permit genetic testing in these patients. These women selfreported being members of the Shona tribe of Zimbabwe and Buganda tribe of Uganda
which are both of Bantu origin which has the highest HLA diversity among humans as well
as lower frequencies of protective HLA B*57 (3-5%) and B*27 alleles (<1%) [27, 33, 34]
than in Caucasian populations (7.0 and 9.2%, respectively) (www.allelefrequencies.net/).
Thus, it is unlikely that any of these genetic polymorphisms could explain the striking
differences in CD4 decline between HIV-infected Ugandan and Zimbabwean women.
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2.3.3 Infecting HIV-1 subtype correlates to disease progression
The infecting HIV-1 isolates in these women were subtyped using the HIV-1 PR, RT and
C2-V3 gp120 env coding regions (Supplementary Figure 2.2&3). As expected, the
Ugandan women, all residing in Kampala, were predominantly infected with subtype A
(68%, n=76) followed by subtype D (28%, n=31), 3 cases of subtype C, and 2 intersubtype
A/D recombinants (Supplementary Figure 2.3a&b). All 174 Zimbabwean women were
infected with HIV-1 subtype C. Based on the infecting subtype, women with subtype C
HIV-1 infections had CD4 T-cell declines (-0.489 cells/week, GEE model) 2.5-fold and
1.6-fold slower than with subtype D and A infections, respectively (-1.231 cells/week and
-0.781 cells/week, GEE model) (Figure 2.1c). The faster CD4 T-cell declines in subtype D
infections also resulted in more patients (45%, n = 14) requiring cART than in women
infected with subtype A and C (28% and 32%) (Supplementary Figure 2.1b). Slow or nonprogression (defined as controllers) was not observed among the subtype D infected
women as compared to the 4% (n=3) and 10% (n=18) in the subtype A and C infected
women, respectively. In contrast, subtype A, D, and C infected women had similar
frequencies of rapid progressors (8.5, 11, and 7.5%, respectively) (Figure 2.1d). Again,
viral levels at set point (Figure 2.2c) in plasma or endocervical mucosa or in plasma during
disease (Figure 2.2a,b,d,e&f) did not differ by subtype (statistical analyses in Figure 2.2g).
To illustrate subtype-specific differences, CD4 T-cell and viral RNA levels were plotted
for 9 subtype C controllers, 9 subtype C typical progressors, and 9 subtype D typical
progressors (Figure 2.3) (subtype A, C, and D rapid, slow, and typical progressors are
shown in Supplementary Figure 2.3). The controller status in subtype C infected patients
is quite evident with less than 0.03 CD4 cells lost per week (based on all 13 controllers)
(Figure 2.3a) as compared to the 0.48 lost per week (linear regression model or 0.49
cells/week, GEE) in the 148 typical subtype C progressors (Figure 2.3b). This rate of CD4
T-cell decline in subtype C is obviously slower than that observed in the typical subtype D
(Figure 2.3c) and subtype A (Supplementary Figure 2.3) progressors (-1.0 and -0.60 CD4
cell loss/week, respectively, linear regression). Viral load increases (following
establishment of viral set point) were similar in all the subtype A, C, and D progressors
(Figure 2.3d,e,f and Supplementary Figure 2.3) but viral loads remained the lowest in the
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subtype C controllers with an actual decrease over time (-4 HIV-1 RNA copies/ml/week;
Figure 2.3d).

2.3.4 Phenotypic differences between HIV-1 subtypes
For this study, we analyzed 143 published and 42 unpublished dual HIV-1 competitions
involving 47 subtype A, D, and C HIV-1 isolates against 25 subtype B isolates (Figure
2.4a&b). In these dual infection/competitions, absolute virus production can vary 100-fold
in PBMCs of different human donors but the relative production (i.e. fitness) of one virus
versus another typically varies less than 10% [10-12]. Subtype C HIV-1 isolates are clearly
less fit in PBMCs than subtype A and D HIV-1 isolates (P<0.002) when competing against
subtype B HIV-1 (Figure 2.4a). Subtype C viruses were not detected (i.e. 100-fold less fit)
in 60% (n=74/123) of the competitions despite the fact that these same subtype C viruses
were readily detected in mono-infections or competitions against other subtype C isolates
[10-12]. These competitions of subtype A, C, and D versus subtype B HIV-1 suggest a
fitness order of HIV-1 subtype B = D > A > C in human PBMC or primary CD4 T-cells
(Figure 2.4) [10-12]. We have previously reported that the replicative fitness of primary
HIV-1 isolates is dominated by the env gene and the rate of cell entry, i.e. the rate limiting
step in HIV-1 replication [9, 11]. Five subtype A, 5 C, and 3 D HIV-1 env genes (from 13
patients) derived from acute/early infection were used to produce chimeric virus (subtype
B NL4-3 backbone) which were then competed against the B-Q0 and B-K44 subtype B
reference viruses (Figure 2.4c&d, respectively). The subtype D Env chimeric viruses were
able to compete with both the B-Q0 and B-K44 reference viruses whereas the subtype A
Env chimeric viruses were less fit (Figure 2.4c&d). In contrast, subtype C Env chimeric
viruses derived from acute/early infection had extremely low replicative fitness or were
completely outcompeted by the B-K44 and B-Q0 reference viruses. Thus, both the HIV-1
subtype C found at acute/early infection and in chronic disease are less fit than subtype A
and D HIV-1 co-circulating in these Bantu populations.
HIV-1 infection can be mediated by cell-to-cell virus transfer or by direct virus infection.
We examined cell-to-cell infection using the more physiological Veritrop system where
transfection of the pREC-nfl HIV-1 vector into 293T effector cells can produce HIV-1
particles (non-infectious) and can mediate fusion with the U87.CD4.CCR5 target cell [28].
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The absolute level of cell-to-cell HIV transmission was similar with 34 acute/early env
genes in pREC-nfl over a 12 h incubation (Supplementary Figure 2.5). Cell-to-cell fusion
kinetics was then measured using a time-of-drug-addition experiment where Enfuvirtide,
an inhibitor of HIV-1 entry, was added at different times post effector/target cell coincubation (Figure 2.5a). Subtype C HIV-1 Env glycoproteins derived from acute/early
infection mediated significantly slower rates of cell-to-cell HIV-1 infection than did
subtype A (P<0.001) or subtype D (P<0.001) Env glycoproteins based on the T 1/2 of
Enfuvirtide inhibition.
Next, we measured the rate of free virus entry into host cells (U87.CD4.CCR5) using these
same 34 acute/early env genes in pREC-nfl. In this case, pREC-nfl was co-transfected with
pMM310 BlaM-Vpr to produce HIV-1 particles harboring a Vpr-BlaM fusion protein
(Figure 2.5b). Upon de novo infection, the HIV_nfl is fully capable of host cell entry which
releases the Vpr-Beta-lactamase to cleave the fluorescent CCF2 dye and change fluorescent
spectra [31] (Figure 2.5b). The rate of virus entry into host cells was the slowest with the
16 HIV_nfl harboring the acute/early subtype C envelopes as compared to those carrying
the subtype A (P<0.05) and subtype D envelopes (P<0.001) (Figure 2.5c&d).
This cohort demonstrated large fitness reductions in the infecting subtype C viruses which
correlated with reductions in entry efficiency. Work developing assays to clarify Group M
virus entry rates and CD4 affinities in different CD4+ T-cell memory cell populations is
ongoing. Preliminary data comparing CD4 attachment receptor affinity is shown below.
These experiments were pursued to explore previous finding that HIV-1 Group M subtypes
differ in their entry rates and rates of HIV induced cell-cell fusion. To clarify the stage of
viral entry that differs most between subtypes, a novel competitive CD4 binding ELISA
was used to quantify the first step of viral entry between viruses from the cohort (Figure
2.6A). Initial experiments were used to establish a protocol and competition timepoints
(Supplementary Figure 3.4). These explorations were used to set a 24-hour competition
period to identify subtype differences. Significant differences after a 24-hour competition
were found between subtypes C and D (p<0.05), and subtypes A and D (p<0.001, T-tests)
(Figure 2.4B). Subtypes C and A did not appear to differ in their affinity for CD4. Subtype
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D showed the greatest affinity for CD4, only losing about 8% of the bound virus when
competed with sCD4. Subtypes A and C lost 30.5% and 48% of bound virus, respectively.

2.4 Discussion
By the 1980s, all the HIV-1 subtypes had emerged, were circulating and recombining in
the Congo basin as well as spreading to neighboring countries/regions [1]. Various HIV-1
subtypes were introduced in multiple geographic regions (South Africa, Zimbabwe,
Brazil, India, etc) [3] by the late 1990s and yet, subtype C HIV-1 rose in prevalence
faster than any other subtype in the heterosexual population (<10% in early 1990s to
>50% today) (Arien et al., 2007) (Figure 2.1). We have previously reported that HIV-1
subtype C isolates had lower replicative fitness in human T-cells and macrophages than
other group M subtypes [10-12] but could only speculate that HIV-1 subtype C may
cause slower disease progression [3]. Aside from regions in Brazil, Tanzania, and Kenya,
HIV-1 subtype C typically dominates in regional pandemics and does not co-circulate at
high frequencies with other HIV-1 subtypes in human populations [3]. As a consequence,
comparing disease progression related to different HIV-1 subtype infections in a single
country or region is very difficult. Thus, we screened for and recruited 300 AHIs in
Ugandan and Zimbabwean women and then followed the natural history of these HIV
infections for 5–9 years in the absence of treatment. With this cohort in Uganda and
Zimbabwe, we have a population of only women, all of Bantu origin, all recruited within
AHI (following heterosexual transmission), and finally, representing the subtype A, C
and D HIV cohorts for sufficient statistical power to measure differences in disease
progression. Independent statisticians at two different institutions (FHI 360 and Case

71

Figure 2.2) CD4+ cell declines in HIV-1 infected Ugandan (n =112) and Zimbabwean
women (n=174) during the natural course of disease. (a) The mean loss of CD4 cells per
mm3 per week of infection in Ugandan and Zimbabwean women and (c) in those women
infected with subtypes A, C, and D. (b) The percentage of rapid progressors and slow
progressors/controllers in Ugandan and Zimbabwean women and (d) in those women
infected with subtypes A, C, and D. Rapid progressors are defined as HIV-1 infected
women with a drop to 200 CD4 cell counts/mm 3 within 2 years of infection and sustained
viral RNA loads greater than 2000 copies/ml. Slow progressors/controllers had viral RNA
loads stable CD4 cell counts above 350 and viral loads < 2000 copies/ml in plasma for >3
years.

72

Western Reserve University) analyzed the cohort data presented herein. The 2-fold
difference in disease progression between these two countries was not attributable to diet,
secondary/opportunistic infections, sexual habits, or age [24]. Of course, we could not
screen for presence or absence of all pathogens, sociodemographic or tribal/population
differences but the questionnaires administered by medical officers at each patient visit
was extensive as was the tests for various clinical chemistries and other health indicators.
Examples of the questionnaire are included in the attached Supplementary Files. We are
currently interested in screening the microbiota in the vaginal tract of these women to
assess possible difference which may be associated with disease progression but again, we
do anticipate differences that segregate by country given the similar diet and diverse human
genetics. Of all the parameters tested, only HIV-1 subtypes could clearly delineate
differences in the rate of CD4 cell decline in blood. Infection with subtype C HIV-1
resulted in the slowest declines in CD4 T-cell counts (0.489 cells/week) as compared to
subtype A (0.781 cells/week) and then subtype D HIV-1 infection with the most rapid
declines in CD4 T-cell counts (1.231 cells/week).
Like other natural history cohorts, rapid disease progression was observed at a 7–9%
frequency regardless of HIV-1 subtype but slow progressors/controllers appeared only in
subtype A and C infections. The differential rates of CD4 T-cell declines (D N A N C) was
still significant when rapid progressors and controllers were removed from the analyses.
We have proposed that a combination of “good” host genetics (e.g. HLA B27 or B57) and
infection with HIV of low replicative fitness may result in “elite” HIV control [35] i.e. a
rare condition in Africa but closely approximated by the 13 subtype C infections with no
declines in CD4 cell counts and b103 copies/ml of virus for N 5 years of infection (Figure
2.3a & f).
Based on previous human genetic studies across Africa [27, 33, 34, 36, 37]
(www.allelefrequencies.net/), we now know that the Bantu population has the greatest
genetic

diversity

of

Homo

sapiens.

Low

prevalence

of

“HIV

protective”

polymorphisms/alleles in the Shona and Buganda tribes (both Bantu) (e.g. <5% of
CCR5Δ32, CCR2a 64I, HLA-B57 and B27) could not explain the dramatic differences in
disease progression. Interestingly, there were no significant differences between countries
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Figure 2.3) Comparing disease progression in a subset of 56 women in Uganda and Zimbabwe infected by different subtypes.
(a)(b)(c)(d)(e) CD4 cell counts/ml were plotted over time in subtype C infected women defined as slow progressors/controllers (a), as
typical progressors (b), in subtype A infected women defined as slow progressors/controllers (c), as typical progressors (d), and in
subtype D infected women defined as typical progressors (e). (f)(g)(h)(i)(j) Viral RNA loads in plasma of subtype C slow progressors,
C typical progressors, A slow progressors, A typical progressors and D typical progressors, respectively.
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or HIV-1 subtypes in the viral RNA levels at set point or over the course of infection. In
our previous report using 188 patients from this cohort and with minimal analyses of follow
up (b3 years), we observed slightly higher viral loads at set point in subtype C and D versus
A infections (p=0.04, ANOVA) that has not held significance when expanding to the 286
patients in this study [22]. Instead, expansion of the cohort size now showed a trend for
lower viral load set points in subtype C infections versus A or D (Supplementary Figure
2.3c). Regardless, it is again important to stress that we did not observe any significant
differences in viral load during disease based on infection by specific HIV-1 subtype.
Most studies examining disease progression in natural history cohorts are now impossible
and unethical based on WHO guidelines for the initiation of cART in all HIV positive
patients regardless of CD4 T-cells counts [38]. With the start of this study in 2000, we
followed WHO/UNAIDS guidelines to treat with CD4 cell counts ≤200/ml which was
controversial because few charities, governments, and international organizations (e.g.
WHO, PEPFAR) had rolled out their treatment programs in Africa. During this ten-year
cohort study, 33% of the participants received treatment at an average of 1,500 days post
infection. Subtype D infected women were ~1.7-fold more likely to receive treatment than
subtype A or C infected women. By modelling the rates of CD4 declines in this natural
history cohort, the projected time to reach ≤200/ml or AIDS in these women was 1.3-fold
longer with subtype C (estimated mean of 12.3 years) than A (9.5 years) and 2.0 fold longer
with C than subtype D (6.2 years). Historical data of subtype B infections in North America
and Europe suggest 6-8 years as an approximate time to reach AIDS (CD4 T-cells <200/ml)
[39, 40] but there are no natural history cohorts from diagnosis (prior to treatment) to
establish accurate estimates. Interestingly, despite different geographical regions, different
human populations, and higher rates of parasitic and other infectious diseases, secondary
and opportunistic infections in Uganda, infections with subtype B in North America and D
in Uganda may have similar rates of CD4 T-cell declines and time to AIDS. Subtype B and
D HIV-1 share the most sequence homology of all subtypes and multiple studies suggest
that subtype B was a sub-branch and “member” of the subtype D super-cluster. Earlier
reports have also described faster disease progression and reduced response to treatment in
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East Africans infected with HIV-1 subtype D than subtype A [15, 16, 20].

Figure 2.4) Relative replicative fitness of HIV-1 subtype A, B, C, and D in human
peripheral blood mononuclear cells. (a) 12 subtype A, 8 subtype D, and 27 subtype C HIV1 primary isolates were competed against 25 subtype B HIV-1 isolates in PHA-activated,
IL2-treated PBMCs of HIV-negative donors in series of published and unpublished studies.
All competitions in PBMCs involved the use of 0.001 infectious units of virus to 1 cell.
The relative production of two viruses in each competition was measured by a radiolabeled
heteroduplex tracking assays or using next generation sequencing10-12. Production of
individual HIV-1 isolates in a dual infection (f0) divided by its initial proportion in the
inoculum (i0) is referred to as the relative fitness (w = f0/i0). In this study, w is expressed
as percent replication of the subtype A, C, or D HIV-1 isolates relative to subtype B HIV1. Assay sensitivity is 100-fold differences in replicative fitness. (b) The relative replicative
fitness of the subtype B HIV-1 isolates in competition with the subtype A, C, and D HIV1 (the reciprocal of a). Symbols with thick outlines represent replicative fitness of the
classified virus at greater than 100-fold or less than 0.01-fold to competitor virus. The
shaded symbols represent the replicative fitness values of primary HIV-1 isolates. The
open/white symbols represent the replicative fitness values of replication-competent
chimeric viruses containing the env gene of a subtype A, C, or D virus within the NL4-3
subtype B backbone. (c) and (d) Replicative fitness of chimeric viruses derived from env
gene of 5 subtype A, 3 subtype D, and 5 subtype C AHI of this cohort. These 13 AHI
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chimeric viruses were competed against the reference subtype B HIV-1 isolates, B-QO (c)
and B-K44 (triplicate).
HIV-1 subtype C isolates are less fit than subtype A which are both less fit than subtype B
and D HIV-1 isolates, a finding established by over 2000 direct head-to-head dual virus
competitions in primary CD4+ T-cells and macrophages from HIV-negative donors of
different races/ethnicities [10-12]. These findings suggest a direct association between the
replicative fitness of HIV-1 and subsequent disease progression. In addition, the HIV-1
env genes derived from 47 women with acute/early infections also showed that subtype C
as compared to subtype A and D were slower in host cell entry by free virus and slower in
cell-to-cell transfer of virus.
In vitro assays of HIV Env engaging with cell surface receptors have also demonstrated a
rate imbalance in the receptor/ligand interactions. Using the Affinofile system, a
transformed cell type with manipulatable levels of surface CD4 and CCR5, the required
receptor densities for infection have been quantified for diverse viral strains [264]. The
results demonstrate that the affinity of the open confirmation of Env is much higher for
CCR5 than the closed confirmation is for CD4. While future work should explore whether
Group M subtype impacts CCR5 affinity, work in this manuscript began with the stage of
viral entry that is the most rate-limiting.
The first stages of HIV infection, those of attachment and cellular entry, have also been
most associated with replicative fitness [265]. These correlations warrant investigations
into the specific step of the entry process that confers this competitive advantage. Our
initial experiments show that the attachment to CD4 receptors correlate with overall entry
rates, patient disease progression and viral replicative fitness in this cohort. While there are
still downstream stages of viral replication to explore, there appears to be little published
variability in the rates of these steps. Future work will explore how variable entry rates,
fusion dynamics, and induced apoptosis differ across the T-cell subsets investigated here.
This will be accomplished using a flow cytometry model and HIV entry-responsive dye
system. These observations, as well as reduced fusion and viral entry efficiency, suggest
that infecting HIV-1 subtype may set the course of subsequent disease progression.
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In summary, this largest natural history cohort of non-subtype B infected women revealed
a significant difference in HIV-1 subtype virulence with ramifications for HIV-1 spread
and treatment in the global epidemic. Women infected with HIV-1 subtype C progressed
to AIDS at least 1.5-fold slower than women infected with subtype A or D. Longer
asymptomatic periods of a subtype C infection will lead to greater probability of
transmission, especially among those discordant couples with unknown infection status
(http://www.who.int/hiv/pub/progressreports/update2014/en/). Using human cervical and
penile explant tissues, transmission “fitness” appears to be similar among most HIV-1
subtypes [12, 41]. Thus, the expansion of HIV-1 subtype C infections in the global
epidemic may be related to the low virulence of subtype C, resulting in long periods of
asymptomatic periods, and leading to increased opportunity for heterosexual transmission
over other HIV-1 subtypes. Ultimately, HIV-1 subtype C may be more “fit” in the human
population based on low subtype virulence and potential high transmission efficiency due
an protracted asymptomatic phase.
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Figure 2.5) Function, cellto-cell
transmission
efficiency and viral fusion
of the Env glycoprotein
derived from acute subtype
A, C, and D HIV-1
infections. The HIV-1 env
gene
of
acute/early
infections in Ugandan and
Zimbabwean women was
cloned into the pREC-nfl
HIV-1 genomic vector by
yeast-based
recombination/gap repair
as described. The function
and co-receptor usage of
the Env glycoprotein from
these 14 subtype A, 4
subtype D, and 16 subtype
C acute/early infections
was accessed using the
Veritrop cell-to-cell fusion
assay. None of the 34 Env
produced in the context of
virus-like particles (VLPs)
could mediate cell fusion
via the CXCR4 co-receptor
within U87.CD4.CXCR4
cells
(below
negative
control and 1000 RLUs)
(data below range of graph
in (a)). (a) Cell-to-cell fusion between the U87.CD4.CCR5 target cells expressing Firefly
Luciferase upon Tat/Rev-mediate expression from pDM1.1 and the 293T effector cells
expressing the 34 Env glycoproteins in context with HIV-1 VLPs. The NL4-3 nfl VLPs
are morphologically identical to wild type HIV but is incapable of reverse transcription and
cannot induce luciferase expression in the target cells. (b) Schematic of the time-of-drugaddition experiment using the Veritrop assay. 2 uM of Enfuvirtide was added at 30 min to
10 hrs post incubation of the effector and target cells. (c) Box plot of the time to 50%
inhibition by Enfuvirtide of cell-to-cell fusion mediated by 34 Env glycoproteins expressed
in context with the HIV-1 VLPs. (c) Schematic of the viral fusion assay which can be
monitored by HIV-1 carrying a BlaM-Vpr fusion protein that cleaves the CCF2 dye in
target cells and changes the fluorescent spectrum. (d) Relative entry over time (0-600 min)
into U87.CD4.CCR5 cells by the chimeric HIV nfl carrying the 14 subtype A, 4 subtype
D, and 16 subtype C Env glycoproteins from acute/early infections. (e) Spectral shift curves
and box plot of the time required for maximal virus entry into U87.CD4.CCR5 cells
carrying the CCF2 dye.
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Figure 2.6) CD4 binding strength via competitive ELISA between HIV-1 subtypes. A)
Schematic of the assay 1) Plates were coated with anti-human-IgG-Fc antibody 2) CD4-Fc
was then attached 3) HIV adheres to the CD4-Fc and 4) Is competed off the plate with free
sCD4. Non-competed controls normalized input via Reverse Transcriptase Assay. Input
virus was also normalized in the same way. B) Percentage of virus removed after 24 hours
of competition with sCD4, smaller numbers suggest greater binding strength. Means
compared via t-test, *p>0.05, ***p>0.001. n=23.

Supplementary Figures
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Supplementary Figure 2.1) The follow up time period and time of cART initiation in the Ugandan and Zimbabwean women enrolled
following acute/early infection. (a) The length of follow-up time for each HIV-infected woman by country and by HIV-1 subtype is
shown in this box plot. The number of days of infection preceding the initiation of cART is also shown. cART was only initiated in
those women with CD4 cell counts below 200 cells/ml and/or who developed severe symptoms of HIV infection (WHO clinical stage
IV or advanced stage III disease). (b) The percentage of HIV-infected woman by country and by HIV-1 subtype that required cART
during the study period.

Supplementary Figure 2.2) CD4+ cell declines in HIV-1 infected Ugandan (n =112) and Zimbabwean women (n=174) during the
natural course of disease. (a) and (b) CD4 cell counts per mm3 as measured in whole blood by FACS Caliber in Ugandan and
Zimbabwean women from AHI to 9 years post infection.
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Supplementary Figure 2.3) Viral RNA loads in blood and cervix during HIV-1 infections.
(a) and (b) Bulk viral RNA viral loads in the plasma of HIV-1 infected Ugandan (n =112)
and Zimbabwean women (n=174) during the course of disease. (c) Viral RNA levels at set
points in the plasma and endocervical swab samples of women from the different countries
and infected by different subtypes (as determined by Loess procedure)22. (d)(e)(f) Bulk
viral RNA loads in the plasma of patients infected with Subtype A, C and D HIV-1
respectively. (g) Statistical significance of GEE models relating infecting HIV-1 subtype
with differences in viral RNA loads over the study period.
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Supplementary Figure 2.4) The HIV-1 subtype classification based on the C2-V3 env
nucleotide sequence. A 450 nt C2-V3 envelop (env) coding regions were amplified from
patient samples and DNA sequenced (see Materials and Methods). The HIV-1 sequences
were edited using BioEdit v7.0.4, aligned using Neighbor joining (ClustalX 43) and
maximum likelihood methods (MUSCLE38). Neighbor joining and maximum likelihood
trees were constructed with SEAVIEW 439 and visualized with FigTree 1.4 shown in this
figure. These env sequences have been previously published22.
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Supplementary Figure 2.5) The HIV-1 subtype classification based on the PR and RT
nucleotide sequences. (a) 300 nt PR and (b) 800 nt RT sequence in the pol gene was PCR
amplified from patient samples, aligned using Neighbor joining (ClustalX 43) and maximum
likelihood methods (MUSCLE38), and presented as trees in the figure. Two HIV-1 RT
sequences from Ugandan women did not cluster with subtypes A, C, or D and were
analyzed for possible intersubtype recombination using RIP and SimPlot
(www.hiv.lanl.gov/content/sequence/HIV/HIVTools.html). (c) Patient 1-515-10526-4 was
infected with a A1/D recombinant. (d) Patient 1-516-10208-5 was infected with a D/A1
recombinant.
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Supplementary Figure 2.6) Example Reverse Transcriptase Assay outputs for CD4
competitive ELISA. This proof-of-concept experiment used timepoints of 12, 24 and 48
hours of sCD4 competition to find the greatest separation in subtype binding strengths.
Assays quantified in Figure 3.4 used a 24 hour endpoint measurement.
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Chapter 3
HIV-1 Group M subtypes selectively deplete memory
and naive T-cell populations at different rates
3.1 Introduction
Rapidly upon infection, the Human Immunodeficiency Virus (HIV) establishes a
transcriptionally silent, latent reservoir of integrated provirus [1]. This pool of infected
cells is what renders HIV infections incurable and is so rapidly generated that even the best
therapies, administered just days after seroconversion, do not prevent its formation [2, 3].
While most circulating cells are transient and have half-lives of a few days to weeks, the
most concerning cells of the HIV reservoir are the CD4+ T-Cell memory subsets which
confer immunological memory for decades [4]. The half-life of these cells is approximately
44 months; estimates suggest remaining on antiretroviral therapy for 70+ years would be
insufficient to clear this latent pool [5]. Therefore, the dynamics of infection and cellular
death in these populations have profound implications for both the individual patient as
well as global HIV eradication strategies.
Integration of the viral genome into the host allows for the virus, even after years of
suppression, to reactivate upon cessation of antiretroviral therapy [1, 6]. Modern
combination antiretroviral therapy (cART) is capable of fully inhibiting viral replication to
the limits of detection, but require lifelong adherence to a regimen of three drugs that may
have pronounced side-effects and can shorten the patient’s lifespan [7-9]. Even with the
success of antiretroviral treatment, only half of the HIV infected population receive cART
and still another of the quarter of the 37 million infected do not know their status [10]. HIV
related deaths have decreased to less than 1 million/year while the number of new
infections remains relatively constant at nearly 2 million a year [10]. Thus, renewed efforts
have focused in an HIV vaccine, due also in part to the successes of the RV144 vaccine
trial. Vaccination strategies that educate the recipients immune system against HIV would
be able to eradicate any reactivated infected cells. Unfortunately, in another cruel twist, the
immense diversity of HIV-1 Group M, which makes up >95% of HIV infections
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worldwide, is so vast that no monovalent vaccine would be capable of targeting every
strain.
This same HIV diversity in the epidemic confers differential drug resistance rates,
transmission abilities, CD4+ T-cell depletion rates, and virulence [11-17]. Perhaps due to
these differences, or other unexplored driver(s), HIV-1 Group M subtypes have spread at
different rates around the world since the virus was identified in 1983 [18, 19]. Most
apparently, subtype C has risen to be the most prevalent strain in the world, representing
~55% of all HIV-1 infections. While other HIV-1 subtypes from Central Africa may have
been introduced earlier, they appeared to have spread slower in many geographical regions.
Subtypes A and D circulate in many of the same regions of Africa but only make up 10
and 4% of all infections worldwide, respectively [18]. As described in the previous
chapter, subtype C HIV-1 appears to replicate slower than subtype A and D in CD4+ T
cells which is directly related to slower disease progression. Of course, the administration
of cART will halt disease progression regardless of the HIV-1 subtype responsible for
infection. However, there may be a differential rate of memory CD4+ T cell infection by
these HIV-1 subtypes prior to treatment, which has implications for the size of the HIV
reservoir during cART. In this chapter we initiated studies to determine the relative
infection and depletion of memory T-cell subsets in women infected with subtype A, C,
and D prior to treatment.
Previous work from our laboratory has demonstrated that infections with HIV-1 Group M
subtype C viruses, relative to other Group M subtypes, have a prolonged time to the onset
of clinical AIDS without differing in viral loads at set point or during chronic infection.
These analyses extensively controlled for host and environmental factors that can skew
measurements of disease progression, including coinfections (particularly Malaria and
Tuberculosis), sexual habits, diet, and hormonal birth control use. However, despite these
controls, some researchers raised questions about how these results align with other
published work. Previously published investigations have suggested that subtype C
infected patients quickly reach clinically defined AIDS (CD4+ T-cell counts below 200
cells/mL in the circulation). With these past analyses in mind, we sought to more deeply
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explore the differential disease progression between subtypes A, C, and D, focusing on the
memory T-cell subsets.
As HIV disease progresses, the canonical measure of pathogenesis is the rate of CD4+ Tcell loss [20]. Differences in these rates have been associated with numerous viral and host
traits, with broad implications for treatment and research. Confoundingly, researchers have
noted that different T-cell populations have varying degrees of infectibility and rates of
apoptosis. Central and effector memory T-cell populations are both more infectible by HIV
than naive CD4+ T cells and have increased densities of CD4 and CCR5 entry receptors
on their surface [21, 22]. Although HIV can gain entry, virus replication only occurs upon
activation of any of these T cell subsets. In general, the memory T-cell subsets are more
commonly activated by common recall antigens (e.g. malaria and TB as well as the
continual HIV replication) than naive T cells responding to novel antigens [23]. Thus,
memory T cells are thought carry the greater burden of HIV replication. Over the course
of HIV disease, the CD4+ T-cell memory subsets may be depleted more quickly than other
subsets due to direct infection and bystander apoptosis. An important question remains
whether HIV Group M subtypes deplete these populations at different rates. Most studies
have measured differential T-cell subset infection in anatomical sites of viral replication,
but this effect is also notable in the circulation.
This also raises the question whether the differences in disease progression extend to the
loss of T-cell memory subsets or if the memory subset decline is independent from disease
progression. Most researchers associate differences in rates of cell death between T-cell
subsets with receptor density on the surface, known to differ between memory T-cell
populations [21, 24]. This may also suggest that the differences observed between HIV
Group M subtypes may be due to differing affinities for these receptors. Downstream viral
cytopathic effects (CPE), or even signaling through Env receptor binding, may compound
over time to drive T-cell depletion.
While the molecular causes of HIV induced cell-death have been explored at-length, it
remains unclear how the vast diversity within Group M infections impacts which cells are
depleted from infected patients, and what drives these differential rates of subset depletion.
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In this manuscript we will investigate how Group M diversity, in particular subtypes A, C
and D from Uganda and Zimbabwe, differentially deplete T-cell memory subsets.

3.2 Methods
3.2.1 Cohort
A cohort of 303 number of HIV positive women from Uganda and Zimbabwe were
monitored throughout their disease progression in the Genital Shedding Study (GS Study),
as described previously (Section 2.2.1, [25-28]). Blood draws were taken at each visit for
viral load titers and white blood cell counts. Over the course of the study, many of these
aliquots were frozen at -80°C and stored for future analysis and a database was created of
CD4, CD8 and viral load test results associated with each sample. A complete history of
this cohort is available in Chapter 2, section 2.2.1 or published previously [25-29].

3.2.2 Archived Samples and Flow Cytometry
Flow cytometry panels were run to quantify CD4+ and CD8+ memory T-cell populations
on a subset of patient white blood cell samples. 69 patients who were enrolled in the study
for a minimum of 1,000 days and had CD4 and CD8 T-cell counts documented from each
visit had a total of 388 samples analyzed, an average of 5.6 timepoints per patient. These
timepoints were selected to fall over the linear range of disease progression; at least 100
days post-infection to avoid the set point. To quantify memory populations in these
archived samples, isolated buffy coats were thawed, spun down and stained with a cocktail
containing CD4-PerCP, CD45RO-FITC, and CCR7-PE or CD8-PerCP, CD45RO-FITC,
CD38-PE, & HLA-DR-APC antibodies per manufacturers protocol. Cells were incubated,
washed and run on an LSR-II (BD Biosciences). Relative numbers of each memory
population were calculated by multiplying the proportion of cells in each gate (Figure 3.1)
by the archived CD4 and CD8 cell counts in the study databases. All lymphocytes were
gated by lymphocyte size using forward and side scatter. Gates described are Naïve CD4+
T-cells

(CD4+/CD45RO-/CCR7+),

Central

Memory

CD4+

T-cells

(CD4+/CD45RO+/CCR7+), Effector Memory CD4+ T-cells (CD4+/CD45RO+/CCR7-),
Naïve CD8+ T-cells (CD8+/CD45RO-), and Memory CD8+ T-cells (CD8+/CD45RO+).
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Figure 3.1) Flow cytometry gating strategy to differentiate memory subsets of CD4+ and
CD8+ T-cells. From the left, lymphocyte gating using Forward and Side Scatter, CD4 and
CD8 positivity using PerCP conjugated antibodies and memory subset quantification using
either CCR7-PE and CD45RO-FITC for CD4+ cells or CD45RO-FITC and CD8-PerCP
for CD8+ cells.

95

96

Markers of activation (HLA-DR and CD38) were also added to CD8+ T-cell Naive and
Memory tubes (Figure 3.1 for quantification and gating).

3.2.3 Models
Marginal generalized estimating equation models were employed to associate viral
diversity with changes in CD4+ T-cell populations, similarly to previous (See Section
2.2.2). Patients codes were used as the subject level to control for varying numbers of
observations per patient. Models were constructed by running univariate correlations
between subtype groups and progressively adding variables. While data normality was
checked, it is not strictly necessary in GEE models. Goodness of fit scores were compared
when adding variables to the model to minimize residuals. Variables were excluded if they
were both insignificant between subtype groups and failed to improve model fit [30]. Error
structures were also compared. Autoregressive error structure (AR(1)) both improved
model fit and most accurately represented the theory of CD4+ T-cell decline in the
literature [31]. In the final model, T-cell counts over time, circulating viral load (RNA
copies/mL), and country of origin were included. All analyses were done using STATA
Version 14 (StataCorp LP, College Station, TX).

3.2.4 Virus Cloning, Propagation and Purification
Viral stocks from patients in the GS cohort were isolated from blood draws at each visit.
Patient viruses from timepoints within 3 months of seroconversion were used in all in-vitro
experiments. Patient Env DNAs in pREC_nfl vectors, lacking the 5’LTR, were generated
(as described in Section 2.2.4). In these vectors the 5’LTR promoter is replaced with a
CMV promoter to generate viral particles that can only infect for a single round but can be
transfected with a vector containing the 5’LTR to reform infectious particles. Patient HIV
isolated env genes were cloned in this way for 30 patients in the cohort that also had
memory T-cell data collected. Virus particles were formed by transfecting into HEK-293T
cells with Fugene 6 (Promega).
Infectious particles from the GS study (full length patient virus) as well as reformed
infectious particles (including only patient Env in a NL4-3 backbone) were propagated for
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these studies. Viruses were propagated in U87*CD4*CCR5 cells (NIH AIDS Cat. No.
4035) in DMEM with 15% fetal bovine serum, 1 µg/ml puromycin, 300 µg/ml G418,
glutamine, and pen/strep. Infections were continued for 7 days and supernatant was
purified and concentrated. Briefly, the supernatant was cleared of cellular debris by
centrifugation at 3,000 RPM. Supernatant was then loaded into a syringe and filtered with
a 0.45µm syringe filter into an Amicon Ultra 15 Filter Unit (100kDa filter, Millipore).
Amicon tubes were spun in a bucket rotor centrifuge at 3,700 RPM for 12 minutes to pass
supernatant through the filter. Using a pipette, the concentrated supernatant from the upper
Amicon filter unit was transferred into a 1.5mL snap-cap tube and filled with DPBS
(Sigma). Tubes were spun at 32,000g in a fixed rotor centrifuge for 1 hour at 4°C.
Supernatant was discarded and viral pellets were resuspended in a small volume of DPBS.

3.2.5 Kaplan Meier Enrollment Analysis
Rates of unenrollment from the GS study were compared using Kaplan Meier curves
generated with Graphpad Prism. Enrollment and unenrollment data came from GS Study
archives. In the GS Study, unenrollment was required upon reaching T-cell counts of 200,
or concurrent counts >300 cells/mL in the circulation or at the discretion of the patient or
clinicians. Patients who left the study with high CD4 counts were excluded from the study,
and only those with CD4 counts below 300 cells/mL and remained in the study for at least
1,000 days were analyzed. Upon unenrollment patients were provided with treatment.
Comparisons were made between infecting subtypes. A total of 282 (114 Ugandan and 168
Zimbabwean) patients were included in this analysis. Curves were statistically compared
using Chi-Square tests with significance cutoffs of p<0.05.
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Figure 3.2) CD4+ T-cell GEE calculated decline rates separated into A) the cohort subset
compared to the previously published entire cohort analysis, B) total CD4+, memory
(CD45R0+), and naive populations (CD45R0-) or C) separating the memory population into its
constitutive central (CCR7+) and effector (CCR7-) memory parts. Infecting subtypes, A, C, or D,
are listed below. P values calculated by GEE models are shown above. n=69.
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3.3 Results
3.3.1 Analyses of CD4+ and CD8+ T-cell subsets during HIV-1
disease
As described in Chapter 2, we recruited 303 women following acute/early infection into
the GS Study. Subsequent follow-up visits were scheduled monthly for the first six months,
every three months for the first two years, and then every six months up to 9.5 years
between 2001 and 2010. At the time, and based on the availability of antiretroviral drugs,
all women were eligible for cART when CD4+ T cell counts fell below 200 per mL of
blood or concurrent counts below 300 per mL. In contrast, the Joint Clinical Research
Centre in Kampala, Uganda has a test-and-treat policy where cART is provided to an HIV
infected individual regardless of the CD4+ T cell count. Thus, this study provides one of
the most comprehensive analyses of the natural history of HIV disease in those infected
with non-subtype B HIV-1. Sample collections during the cohort study were also extensive
with blood, vaginal, and cervical samples collected every 3 months. PBMCs were purified
from blood every 3 months.
In this study we compared rates of T-cell loss between Group M subsets to identify the role
of memory T-cell depletion in HIV disease progression. Using cryopreserved, purified
PBMCs, we stained the cells with either anti-CD4, CD45R0, and CCR7 antibodies (for
CD4+ subsets) or anti-CD8, CD45R0, CD38 and HLA-DR antibodies (for CD8+ subsets).
Flow assisted cell sorting (FACS) identified the percentages of T-cell subsets. CD4+
populations

identified

were

CD4+/CCR7+/CD45R0-

T-cells

(naive),

CD4+/CCR7+/CD45R0+ T-cells (central memory), and CD4+/CD45R0+/CCR7- (effector
memory) as described in Figure 3.1A. CD8+ populations identified were CD8+/CD45R0(naive) and CD8+/CD45R0+ (memory) as described in Figure 3.1B.
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3.3.2 HIV Subtype impacts depletion of CD4+ and CD8+
populations
We first compared the CD4+ T-cell declines between the subgroup samples (69 patients)
relative to the total patient population (303 patients) over the course of infection (Figure
3.2A). Generalized estimating equation models are considered the gold standard for
longitudinal data analysis in order to account for covariance due to multiple measurements
within a single patient over time. This model also corrects for varying numbers of
observations per patient and allows for flexible error structures. Autoregressive error
structures (AR-1) suggest that the correlation between two cell count measurements in a
given patient is a function of the time between the visits, with reducing correlations over
greater time. These relationships most accurately resemble the data and dynamics of the
human immune system generally and were employed in all the analyses herein.
The results reconfirm previous conclusions about differential disease progression between
subtypes even with a limited number of patient samples available (Figure 3.2A). Subtype
C infections showed a highly statistically significant reduction in the rate of all CD4+ TCell loss, about 0.63 cells per week, relative to that of subtype A (p<0.0001, GEE), losing
about 1.03 cells per week, both of which differ from subtype D, which loses about 1.22
cells per week (all pairwise comparisons p<0.0001, GEE) (Figure 3.2B). Our analyses also
found that while viral load correlates with the loss of CD4+ cells, these relationships do
not differ between subtypes (Supplementary Figure 3.3).
Pooled memory subsets, CD4+/CD45R0+ T-cells, also showed reductions in pathogenesis
by subtype C relative to A and D (C vs. A, p<0.0001, GEE; C vs. D, p=0.019, GEE, Figure
3.2B). In other words, the decline in the memory CD45R0+ T-cells was slower when a
patient was infected with subtype C. Analyses of this cohort subset showed that the more
rapid declines in memory CD45R0+ T-cells with HIV-1 A and D infections did not
significantly differ from each other and does not suggest, based on the memory CD45R0+
T-cell decline data alone, that subtype D HIV is more pathogenic. This pooled memory
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population also displays a wide range of memory CD45R0+ T-cell losses during subtype
C infection (+/- 0.75 cells per week) with some subtype C infected individuals having no
decline of memory CD4+ T-cells during ~6.5 years of infection. In contrast, all 118
subtype A and D infections had a progressive loss in the memory CD4+ T-cell populations.
The CD4+ naive population did not change in frequency over the course of infection
regardless of infecting subtype (Figure 3.2A).
To further interrogate the individual memory subsets, the central and effector memory
populations were separated and compared directly by staining for CCR7 and CD45R0
(Figure 3.2C). Statistically significant differences based on infecting subtype can be
observed in the effector memory CD4+ T cells over the ~6.5 years of infection (C vs. A,
p<0.0001, GEE; C vs. D, p=0.004, GEE, Figure 3.2C). Separating memory T-cells
populations showed that central memory T-cell counts did not significantly decline during
HIV infection (p=0.1271, Linear reg., Supplementary Figure 3.1) and there were also no
significant differences related to the infecting HIV-1 subtype (Figure 3.2C).
CD8+ T-cells, while not directly infected by HIV, have been shown to lose function and
decline due to bystander effects during untreated HIV disease [34]. Our measurements of
CD8+ T-cell populations are unable to show these losses of cells in subtype A and C
infections, but the most pathogenic subtype, subtype D, shows consistent and significant
CD8+ cell depletion of about 0.5 cells/week (Figure 3.3). These declines in subtype D
CD8+ T-cell populations are visible in total cell measurements but are largely driven by
the loss of memory cells, which only declined in subtype D infections. Numbers of naive
CD8+ T-cells did not change in prevalence in these patients
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Figure 3.3) CD8+ T-cell GEE calculated decline rates separated into memory (CD45R0+),
and naive (CD45R0-) populations. Infecting subtype is listed below. P values calculated
by GEE models are shown above. n=69.
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Figure 3.4) CD4+ and CD8+ memory T-cell dynamics (CD45R0+) for 27 patients with
typical disease progression for infections by each subtype in women who participated in
the GS Study in Uganda and Zimbabwe.
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during 6.5 years of infection and regardless of the infecting subtype.
Typical HIV disease depletion of CD4+ and CD8+ memory T-cells for patients infected
with each Group M subtype are shown in Figure 3.4. These example patient measurements
provide a better visualization of the steady linear depletion of these subsets, as well as the
subtype D specific depletion of CD8+ memory T-cells. Patient subtype A infections largely
resembled subtype D depletion of CD8+ memory T-cells. Subtype C infections remain
largely steady over the course of infection, with clear proliferative events between visits
that are not seen in the other Group M subtypes. All HIV infected patients experienced
CD4+ memory T-cell depletion over the 6.5 years of monitoring. These cell losses appear
consistent and steady in both subtype A and D infections, while subtype C, mirroring CD8+
memory T-cells, show greater stochasticity.
The simultaneous expression of CD38 and HLA-DR was used a marker for the activated
CD8+ T-cell population but did not identify subtype specific activation in naive or memory
populations during HIV infection (Supplemental Figure 3.2). There was however a trend
for higher CD8+ T-cell populations in the subtype C infected patients as compared to those
infected with subtype A and D. This trend was most apparent in the memory and activated
CD8+ T-cell populations.
As described above, subtype C infections led to apparent slower declines in the effector
memory CD4+ T-cell population than did infections with subtypes A or D. Indeed, the
slower declines in the entire CD4+ T lymphocyte population suggest slower disease
progression by subtype C, which may be attributable to both a reduced activation and
transition of memory CD4+ T-cells to effector memory T-cells. The effector memory Tcells could die due to TCR initiated-programmed apoptosis, direct HIV cytopathogenicity,
or HIV-related direct or bystander apoptosis. Importantly, viral load analyses on both the
cohort subsets analyzed here, as well as the broader cohort, have not identified lower
circulating virus concentrations during subtype C infections (p=0.219, ANOVA,
Supplementary Figure 3.3).
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Given the wide range in the CD4+ T-cells memory and CD8+ memory T-cell counts
(CD45R0+) over the course of subtype C infections, we performed a correlative analysis
between these two cell types to investigate differing relationships between these cell types
during Group M subtype infections (Figure 3.4). Linear regressions by infecting subtype
showed statistically significant correlations between the dynamics of the CD4 and CD8
memory subsets (Linear regression, p=0.002). These correlations highlight the CD4+ Tcell independent depletion of CD8+ T-cells during subtype D infections. Infections with
subtype D are the only subtype to show a negative correlation between CD4+ and CD8+
memory T-cells (Figure 3.5). The depletion of CD8+ T-cells during subtype D disease has
major implications for viral control but, without increased activation markers in CD8+ Tcell populations, relies on a yet undiscovered mechanism.

3.3.3 Rates of study unenrollment agree with other
pathogenicity measurements
Other studies on pathogenicity of HIV-1 Group M subtypes used the time to clinical AIDS
as a measure of pathogenicity. We used unenrollment from the study as a proxy
measurement for clinical AIDS since patients were unenrolled to receive treatment after
concurrent CD4+ T-cell counts below 300 cells/mL in their circulation. Subtypes C and A
were statistically indistinguishable (p=0.9451), while subtype D infected patients
unenrolled earlier than subtype C (p=0.0444) and nearly differed from subtype A
(p=0.0541) (Figure 3.6).
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Figure 3.5) Correlations between CD4+ memory T-cells and CD8+ memory T-cells
(CD45R0+ populations) between Group M subtype infections. Observations made between
100 days post infection and 2,100 days post infection. Comparisons between the slopes of
best fit lines used linear regression, p=0.002, n=338).
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Figure 3.6) Kaplan Meier analysis for patient enrollment by infecting subtype. Patients
included in this analysis must have remained in the study for >1000 days and reached a
CD4 count below 300 cells/mL. Subtype A median enrollment was 2,239 days, subtype C
was 2,169 days, and subtype D was 1,367 days. n=282.

108

3.4 Discussion
In both HIV and SIV infections, many of the immunodeficiency symptoms and
opportunistic infections are directly related to the loss of effector memory cells and the
ability of these cells to rapidly respond to non-HIV recall antigens [35, 36]. Primate models
and other investigations have shown that these cells are the first to become exhausted and
undergo apoptosis. Here we show that effector memory cells are the primary CD4+
population to be depleted during untreated infection while naive and central memory CD4+
T-cells are nearly unimpacted, regardless of infecting subtype.
The same pattern of differential pathogenicity of the most prevalent Group M subtypes in
Africa is visible in T-cell memory (CD45R0+) population declines. Patients infected with
subtype A and D viruses lose their CD4+ memory T-cells at about double the rate of
subtype C. While subtype C viruses appear highly variable in their effects on memory Tcells, the more pathogenic subtypes A and D specifically deplete CD4+ effector memory
T-cells without depleting central memory or naive populations. These populations that
remain unchanged over HIV-1 infection have been documented to be poorly infected,
largely transcriptionally inactive, and non-dividing [24, 37]. While some depletion of these
subsets may be expected due to bystander apoptosis, the lack of viral replication limits
cytopathic effects, and the intrinsic apoptosis pathway.
Infections with subtype C viruses induced varying CD8+ T-cell responses, over a much
broader range than subtype A or D disease. This heterogeneous response to subtype C
infection warrants future work to identify correlates of CD8+ T-cell proliferation.
Published literature has detailed the prevalence of CTL epitopes in conserved regions of
the subtype C accessory protein Nef, and the overwhelming preference of the CTL
response to Nef epitopes in subtype C infections (97.5% of epitopes) [38, 39]. Recent
subtype C reference strains from Brazil have also been described that harbor mutations in
Nef residue A84 that greatly reduce MHC class I downregulation [40]. These types of
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mutations may leave subtype C open to CTL clearance of infected cells and contribute to
the differential pathogenesis observed here.
Investigations into pathogenicity and fitness have routinely shown that subtype D is the
most fit and pathogenic strain of HIV-1 Group M [41-43]. Using unenrollment from the
GS study as an endpoint mimicking clinical AIDS, we compared enrollment by infecting
subtype. While subtypes A and C did not differ in their rates of unenrollment, subtype D
patients unenrolled at much greater rate. Results presented here also suggest that subtype
D is unique in its depletion of CD8+ memory populations. In the absence of viral escape
mutations, CD8+ T-cells are the primary mode of infected cell clearance, the breadth of
which is linked to disease control [44]. However, it remains possible that the skew towards
a memory phenotype (CD45R0+) CD8+ T-cell is a product of the disruption of natural
lineage maturation in subtype C HIV infected patients [45].

3.4.1 Preferential depletion of effector memory T-cells during
HIV infection
Simple models of T-cell homeostasis and activation show an accelerating depletion of the
T-cell populations [31, 46]. As the immune system loses cells to activation-induced
apoptosis, bystander apoptosis, and HIV cytopathic effects (CPEs), the bone marrow
releases new uninfected naive target cells which, according to the second hypothesis,
should migrate to inflammatory sites and become infected themselves. This “fuel to the
fire” model would grow exponentially and deplete the immune system in months rather
than years. However, patients rarely display this cell-loss dynamic and almost always have
a slower, near linear progressive effector and memory effector T-cell depletion over the
asymptomatic period of infection.
One explanation draws from the finding that mature, peripheral T-lymphocytes are the
primary source of new CD4+ T-cells in the periphery [47]. Specifically, mature T-cells
transferred between HIV discordant twins were found to persist for months and expand
significantly. HIV patients with unsuppressed viremia undergo chronic immune activation
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and inflammation due to huge amounts of antigen produced from productively infected
cells. The antigen naive HIV-specific T-cell population, in response to cognate antigen
presentation, proliferate into transcriptionally active effector cells. These cells are well
documented to be preferentially infected by HIV, fueling viral replication, cytopathic
effects and releasing more HIV antigens [22]. This cycle of activation seeds HIV-specific
effector memory populations, long-lived cells capable of producing new virions for
decades, further fueling post-activation apoptosis. It also results in the persistence of HIV
infected cells in the periphery while gradually depleting the activated effector T-cell
populations. This theory of T-cell depletion particularly highlights the role of inflammation
and T-cell activation in their eventual apoptosis, while downplaying the impact of viral
cytopathic effects.

3.4.2 Implications
Replicative fitness, CD4+ effector memory T-cell depletion, and cellular entry efficiency
strongly correlate in a cohort of HIV-1 infected women. Subtype C displayed the least
efficient attachment affinities, entry rates, relative fitness scores, and caused a disease that
progressed at about half the rate of subtype D infections. The consistent patterns across
widely differing analyses lends credence to these conclusions. Maintenance of CTLs
during subtype C disease, and their gradual depletion during subtype D disease, may be
major drivers of pathogenesis differences.
However, regardless of subtype, HIV infections remain incurable. To fully consider
strategies to eradicate HIV in lieu of a cure, the field must better understand the diversity
of diseases caused by this virus, whether current estimates of undiagnosed infections are
accurate and how treatment must be prioritized to minimize future transmission. To target
the latent reservoir of integrated HIV-1 provirus, it’s critical to understand the dynamics of
the cell types that harbor it. Most importantly, these considerations must be made using the
full diversity of HIV-1 Group M, not just subtype B.
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Supplementary Figure 3.1) Cohort subset CD4+ T-cell Central Memory
(CD4+/CD45R0+/CCR7+) cell counts over the course of HIV-1 infection. Observations
within AHI, <100 days post infection, were excluded. Linear regression comparison with
zero slope, p=0.1271. n=338.

112

Supplementary Figure 3.2) CD8+ T-cells trends in activation markers CD38 and HLADR over the course of infection by HIV Group M subtypes. Gating strategy shown on the
left and GEE calculated rates of change shown in the box plot on the right. n=57.
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Supplementary Figure 3.3) Cohort subset viral loads for all visits post AHI, <100 days
post infection. Lines and dots denote Group M subtype, green = D, red = C, blue = A.
Nonlinear regression between curves for each subtype, p=0.219. n=388.
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Chapter 4
Discussion
4.1 Viral Fitness, Disease Progression, and CD4 Binding
Affinity
This dissertation conclusively supports the link between replicative fitness and disease
progression in HIV-1 Group M subtypes A, C, and D from a cohort of women in Uganda
and Zimbabwe. Patterns of T-cell depletion strongly correlate with patterns of replicative
fitness in activated PBMCs, such that subtype D is fitter and more pathogenic than
subtype A, both of which are greater than subtype C (Figures 2.2 & 2.4). The patterns of
cell depletion extend to memory subsets of CD4+ T-cells, but not naive or central
memory T-cells (Figure 3.2). These data substantiate the notion that effector cells, and
particularly effector memory cells, are the most depleted populations during untreated
HIV disease. Chronic inflammation and immune activation drive the expansion and
subsequent apoptosis of effector T-cells in the periphery, generate more infectible targets,
release HIV antigens, and signal bystander apoptosis [1-4].
The size of the cytotoxic T-lymphocyte (CTL) population that target HIV-1 are
associated with disease control and limiting viremia [5]. Analyses of CD8+ memory Tcell population dynamics in the GS cohort demonstrate that only subtype D causes a
statistically significant reduction in the number of circulating cells, while naive and
activated subsets remained unchanged (Figure 3.3). These results demonstrate a possible
mechanism of the rapid disease progression associated with subtype D infections, due to
a depleted CTL response. This CD8+ cell depletion in subtype D infections appears to
begin early in infection and does not correlate with losses of CD4+ T-cells or CD4+
memory T-cell subsets. Subtype C infections displayed a particularly wide range of effect
on CD8+ T-cell counts, suggesting in some participants that CTLs proliferate even during
active infection. This data may clarify why subtype C disease progresses so slowly
relative to other Group M subtypes and warrants additional exploration. Studies
attempting to predict CTL epitopes in subtype C viruses highlight the flaws in studying
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only subtype B infections, thus the unique immune pressure on HIV subtype C by CTLs
remains to be explored [6].
Links between fitness and pathogenesis have been previously suggested, however few
studies have adequately addressed such a question [7-9]. In the analyses presented herein,
we addressed many of the failings of previous studies through extensive medical
surveying, PCR and seroconversion tests to closely estimate time of infection and
accounted for host diversity more effectively than prior investigations. Finally, despite
extensive analyses we did not find an impact of viral load, diet, environment, host
genotype, sexual habits, country of origin, or hormonal birth control use that better
explains the differences associated with HIV-1 Group M subtype. HIV disease, as with
all human disease, is a complex system with many factors determining immune cell
apoptosis and depletion. These analyses required very large numbers of observations in a
large cohort to reach statistical significance while controlling for the other measurable
factors known to impact pathogenesis.
Previous work from our laboratory utilized diverse chimeric viruses to map the primary
drivers of viral suppression in lieu of treatment. That study identified the Env
glycoprotein, the viral protein responsible for virion attachment and cellular entry, to be
the largest single contributor to elite viral suppression between HIV-1 clones [10]. Data
presented here, using viruses from the GS Study cohort, also strongly implicated a role of
viral attachment, entry, and fusion in CD4+ T-cells to account for fitness differences and,
in turn, differences in virulence. The rate of cell-cell fusion, as a corollary to syncytia
formation in the lymph nodes, showed statistically significant rate increases in subtypes
A and D relative to subtype C (Figure 2.5b&c). These syncytia are a major marker of
advanced HIV disease, disrupting lymph node architecture and interrupting immune
system function. We also found that these rate changes extend to a viral particle entry
model, to cover all modes of cell infection (Figure 2.5d&e). These rates of fusion and
viral particle entry are likely driven by CD4 binding affinity differences (Figure 3.4).
The differences between HIV-1 subtypes presented in this work are consistent with the
patterns reported by our group and others [8, 11-17]. Investigations into Gag-Protease,
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replicative fitness, disease progression, susceptibility to fitness-reducing mutations, viral
entry rates, CD4 affinity, and proviral decay all identified subtype C as the least and
subtype D as the most effective or fit subtype of those compared [8, 11-13, 15-25], each
of which may be contributors to fitness differences between subtypes. It must be
hypothesized that the combined reductions in fitness in subtype C might be adaptive.

4.2 Subtype C Epidemic spread
Over the past four decades HIV-1 has spread around the world. However, this spread has
not been equally distributed between the Group M subtypes. Subtype C expanded the
most and is currently the most prevalent in the world (55% of HIV-1 infections) [21, 24],
with little research focusing on identifying why. The work presented here has identified
significant reductions in pathogenicity in subtype C that may have driven this expansion
[11, 12, 26, 27]. Mathematical models that estimate the effects of prolonged
asymptomatic disease have shown strong positive correlations with disease spread [28,
29]. It is worth noting that these models typically use data from more rapid disease
outbreaks like Influenza A or SARS and may not accurately predict future HIV
transmissions.
South Africa has the highest incidence of HIV infections in Africa, 18.8% of adults 1549, while containing the highest prevalence of subtype C HIV in the world, 95%. The
prevalence of subtype C infections in Brazil has also increased in the last decade while
other subtypes plateaued [21, 24, 30]. But these findings remain limited due to the small
number of appropriate populations, limited funding, and limitations of ethical human
research.
Past work from our laboratory suggest that these fitness differences between subtypes are
consistent between regions [21, 22], but further analyses are required to demonstrate
consistent patterns from other continents. Work from others has demonstrated the rapid
disease progression of subtype D in Kenya, Rwanda, South Africa, Uganda, and Zambia
[17, 31, 32]. The patterns of fitness in other regions appear to be strong indicators of
pathogenesis as well. However, future work should continue to examine HIV-1 subtypes
A, C, and D fitness and disease progression outside of Eastern and Southern Africa.

122

Ideally, future metanalyses of archived monitoring data from untreated HIV+ patients
from around the world could assemble a much broader database than any single study.
The results from the GS cohort suggest that human genotype has a significant impact on
basal CD4+ T-cell counts but when accounted for, no other patient background
measurements were necessary to identify subtype differences in pathogenesis.
Understandably, the managers of trial data will be reluctant to share their patient records,
and these analyses are unlikely to come to fruition, but are likely one of the few
remaining avenues to investigate untreated HIV disease progression.
It is also possible that the predominance of subtype C has been fueled by founder effects
alone, since most HIV epidemics are established by a relatively small number of infected
people with limited viral diversity [33]. Subtype B is documented to be one of the most
pathogenic forms of HIV-1, and expanded into North America, Europe, the Caribbean,
South America and Australia. These epidemics provide contradictory evidence to the
hypothesis that fitness reductions spread HIV. Unfortunately, it is difficult to compare
HIV transmission patterns between eras and populations. The difference made by
HAART cannot be discounted and the overall decline of HIV transmissions may provide
different selection pressures on the virus than was present in the 1960s and 70s.

4.3 GS Study Cohort
Research of human pathogens requires innovative research strategies and extreme care to
maintain ethical research practices. In the design of the GS Study, from which the disease
progression data was mined, it was extremely important to the study directors to provide
as many resources to the participants as possible. While not required for ethics approval,
counselling, frequent medical examinations and treatment upon unenrollment were
provided to all participants. This was the first study of its kind to provide treatment to
participants after enrollment, thus the study coordinators could state that the research and
use of its data were navigated in the most ethical manner available. Despite this, later
studies, like the 2015 Strategic Timing of Antiretroviral Treatment (START) study,
found that delaying HIV treatment in the infected had severe consequences on long-term
survival and disease management, even when these participants maintained CD4+ T-cell
counts above 500 cells/mL [34]. Following these results, the WHO established new rules
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about the ethical research of HIV+ populations that require treatment to be provided upon
HIV diagnosis. These rules would make repeating the GS study, or any study for that
matter, with similar approaches, impossible. Since these data are irreplaceable and
unrepeatable, it is critical to maximize what we can learn from it.
The GS study is also unique in its location and participants. Few human populations are
as well suited to this study design as the enrolled Ugandan and Zimbabwean women. The
human genetic diversity in the region is so vast as to mimic a much broader study area.
This allowed for an economically efficient study design while also controlling for human
genotype, a criterion not assessed in previous investigations. Genetic diversity and other
covariates between the Ugandan and Zimbabwean populations did impact our analyses,
primarily in the baseline CD4+ T-cell counts, prior to infection. Zimbabwean women
naturally had lower CD4+ T-cell counts, which were suggested to play a significant role
in how their diseases progressed. During the analysis we worked to address these
concerns, both by including baseline T-cell counts in our model and by measuring CD4+
cell loss as a percentage of the participants starting cell count. Each of these strategies did
little to change the results of the analysis, and only served to add variability and reduce
overall model fit scores.
Finally, the GS study data identified the date of HIV infection in a more analytically
appropriate manner. Rather than enrolling HIV+ populations, the GS study enrolled
participants from the HC-HIV study upon early PCR or seroconversion test. These
diagnoses were then confirmed via PCR and a best estimate at the date of infection was
calculated. This differs dramatically from other studies which estimate HIV infection date
by viral load retrograde extrapolation [35, 36]. These errors in enrollment strategy
typically overestimate the time since infection in participants with higher viral loads and
more rapid disease progression, effectively dampening differences between participants.

4.4 Future Directions
Work is ongoing to explore the results presented herein. Varying rates of entry, cell-cell
fusion and affinities for CD4 can be explained either through variation of viral surface
Env expression or mutations that confer greater binding affinity and kinetic rate. HIV-1
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subtypes that have low Env density on the viral surface would slow the receptor-ligand
interaction rate and could account for the whole-virus affinity for CD4. The competitive
ELISA presented in Chapter 2 measured CD4 affinity by an entire viral particle and not
purified Env protein (Figure 2.6). Future work could also explore the per-Env trimer
affinity differences for CD4 and would be worth pursuing regardless of the results of Env
quantification experiments. Preliminary analyses to quantify the number of Env trimers
per viral particle have failed to find differences in Env density. However, the fluorescent
western blot protocol used has a relatively high limit of detection for the picogram
quantities of Env we are trying to quantify. Transition to a chemiluminescent assay using
antibodies conjugated to horseradish peroxidase (HRP) to amplify the band signal [37].
Overall, these studies are especially difficult due to the variability between the HIV
subtypes being measured. DNA sequence homology between subtypes A, C and D is
about 85% with the greatest differences found in the env gene sequence. The impact on
the binding strength of many monoclonal antibodies with epitopes in HIV Env has been
documented and varies depending on subtype [38]. The monoclonal antibody B13 binds
to the CD4 binding site (CD4bs) and is the most consistent antibody when binding
diverse HIV strains [10, 39, 40]. Unfortunately, this antibody requires high titers for
efficient binding and the linear epitope requires significant denaturing steps before
blotting. This relatively poor interaction highlights the necessity of signal amplification
through chemiluminescence.
Expression differences of HIV-1 Env between subtypes would raise future questions
about the subtype specific mechanisms at work. Both degradation in an endocytic
compartment following reinternalization and weakened Gag-Env interactions during viral
assembly and budding have been suggested [41]. Protocols developed in our laboratory
for surface plasmon resonance (SPR) experiments would be able to measure both EnvCD4 and Env-Gag interactions per trimer to clarify these binding results. Sample
preparation would need to be highly purified to detect signal differences, likely requiring
purified protein of different subtypes to be ordered from the NIH AIDS Reagent
repository. These experiments could explore CD4 affinity for all available viruses from
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around the world to see if the differences found in Uganda and Zimbabwe are
maintained.
A flow cytometry panel utilizing HIV entry sensitive dye and fluorescent antibodies
differentiating lymphocyte populations is also being developed. This assay, when fully
developed, could measure viral entry by cell type. Viruses used in these experiments
contain dsRed2 sequences between the env and nef genes to quantify productive infection
as well [42]. Long-term infection assays could use markers of pyroptosis (activated
caspase 1) and apoptosis (activated caspase 9 or caspase 3) to clarify the mode of cell
death, measured between HIV-1 subtypes and across all CD4 and CD8 T-cell subsets.
Finally, the in vitro assays presented in this dissertation were developed to move into
activated PBMC cultures from uninfected participants to explore differential virus entry,
fusion and CD4 binding in the T-cell memory populations. Implementation and
troubleshooting of these assays were beyond the scope of this work but is progressing to
clarify the mode of cell death in these memory lymphocytes. The typical forms of T-cell
death during HIV infection are bystander apoptosis, HIV cytopathic effects and post-TCR
stimulation apoptosis. The first two of these modes have cannot be addressed by data
presented in this thesis and are hotly debated in the field. The final, the role of TCR
stimulation and immune activation, has been a focus of this research, however conclusive
evidence of immune stimulation-based T-cell contraction is elusive.
The engagement of the viral particle with the CD4 receptor, which we demonstrate here
is heavily influenced by HIV subtype, may serve to “prime” these cells for future
activation and expansion. Assays allowing HIV attachment but preventing cell entry
show a significant increase in future activation levels in diverse T-cell populations.
Future work will also explore whether the CD4 binding strength of the viruses
themselves functions to modulate this chronic activation observed in HIV disease. While
evidence in this dissertation is simply correlative, that subtype C has both a reduced CD4
binding strength as well as a slower pathogenesis, future studies will investigate subtype
induced levels of immune activation that could exacerbate disease.
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4.5 Implications
4.5.1 Latency
The transcriptionally latent viral reservoir remains the final challenge in curing HIV [43,
44]. “Shock and kill” strategies seeking to reactivate and destroy this pool of integrated
provirus are in development. New data from a Rakai, Uganda cohort of primarily
infections by Group M subtypes A and D, revealed that North Americans, infected with
subtype B viruses, typically have larger pools of latent provirus than participants in the
African cohort [45]. The relative size of the subtype C latent proviral pool remains to be
quantified. This result strongly suggests a role for viral diversity in the size of the latent
reservoir, with many future questions to be addressed.
The impact of HIV diversity on latency may provide targets for cure strategies that push
the integrated HIV provirus so deep into a latent state that it is unable to reactivate. These
strategies, catchily termed “Block and Lock” therapies, are attempting to identify host
factors to promote histone translocation, methylation and deacetylation near the
integrated viral promoter to prevent future reactivation [46]. If Group M subtypes have
naturally evolved ways for the virus to promote greater integration and latency, then this
may become a viable therapeutic to limit viral rebound after ART cessation and lower the
bar for “Shock and Kill” effectiveness.

4.5.2 HIV Cure
Cure strategies, elevated by the results of the RV144 Thai Trial vaccine, have begun to
focus on non-neutralizing IgG antibodies due to their negative correlations with infection
[47]. These antibodies are unable to neutralize the virus directly, but instead capture the
virus in aggregates. Viruses bound by these antibodies cannot infect new cells and are
instead phagocytosed [48]. Critically, these antibodies do not bind infected cells and
promote antibody-dependent cellular cytotoxicity, instead relying on other forms of
infected cell clearance. The data presented herein suggest that a vaccine that successfully
stimulates this subclass of IgG antibodies may struggle to control advanced subtype D
disease due to the unique depletion of CD8+ T-cells (Figure 3.3). CD8+ T-cells, or
cytotoxic T lymphocytes (CTLs) play a key role in destroying infected cells [3]. Potential
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pitfalls like these highlight the importance of considering the broader HIV-1 Group M
diversity while moving forward. Neutralizing antibody research has already reached this
conclusion and future HIV vaccine trials based in South Africa will utilize subtype C Env
proteins in their formulation [49, 50]. These upcoming trials are likely going to be the
most impactful in the history of the field, due to the better understanding of HIV control
from the RV144 trial and incorporation of the most prevalent subtype in the pandemic,
subtype C, in the vaccine itself.
While optimism abounds following RV144, it is still important to find methods to limit
HIV transmission in case a vaccine doesn’t materialize. The WHO goal for 2020 is for all
countries to achieve 90/90/90 targets: 90% of HIV+ individuals aware of their status,
90% of those patients to be on treatment and 90% of patients on treatment to be fully
virally suppressed [51]. These goals are made especially difficult when considering the
data presented on subtype C disease progression [52]. Expanded time to reach clinical
AIDS following infection with a subtype C HIV-1 virus primarily expands the
asymptomatic phase of infection. Estimates of prevalence of HIV can be badly skewed
given a disease progression that doubles the length of time patients remain asymptomatic
[53]. Misjudging the prevalence of HIV may be an especially dangerous mistake as
subtype C moves into regions with huge populations, like India, China and southeast
Asia. The delay in apparent symptoms of disease, when combined with local
governments that are resistant to international interference, can allow epidemics to
immerge quickly and overwhelm the limited resources to reach 90/90/90 targets. While
these warnings may seem dire, the rapid expansion of the HIV epidemic in Russia and
other former soviet states among intravenous drug using populations underscores this
reality [54, 55]. Refusal to allow international organizations into Russia to accurately test
HIV prevalence and incidence rates leaves this region and the whole world at risk.
Research has historically, and continues to, focus on subtype B as a model of all HIV
infections. Despite research highlighting major differences between subtypes, nearly
every model strain of HIV-1 used in laboratories around the world is subtype B in origin
[56]. Subtype specific traits impact how drug resistance develops, and in countries with
limited available ART regimens, controlling HIV drug resistance will be the key driver in
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reducing infection rates [9]. For example, China, a country with a burgeoning HIV
epidemic, limits the import of foreign made HIV drugs [57]. These limits seek to bolster
the Chinese pharmaceutical industry but prevent new therapeutics from reaching Chinese
patients. The net effect is the prevailing use of older drug regimens that are prone to
resistance. Viral resistance to newly developed ART drugs, like dolutegravir, an integrase
inhibitor, are much less common relative to previous generations. Unfortunately, these
drugs are currently blocked from import by the Chinese government. The broad genetic
diversity in the infecting HIV strains in the country allows for recombination and
possesses even more drug resistance capacity than a single HIV type would. Estimating
future drug resistance on studies of subtype B alone woefully misjudge the problem at
hand.

4.5.3 HIV Policy
HIV is not curable, regardless of subtype. However, that doesn’t imply that differences in
pathogenicity between viral strains are not useful to inform policy and political decision
about the epidemic. Renewed focus must be placed on diagnosing HIV+ patients,
particularly in areas with circulating subtype C viruses, as HIV-related symptoms are
likely not to appear until years after infection, perhaps reducing rates of diagnosis. Efforts
must be made to place every diagnosed patient onto treatment as soon as possible, per the
recommendations of the START study and WHO research guidelines. However, given
the limited funding available, the aggressiveness of subtype D infections may aid in
triaging patients of Sub-Saharan Africa. Economic retractions have pushed the
President’s Emergency Plan for AIDS Relief (PEPFAR), the largest single contributor to
HAART in Africa, to decline in recent years, limiting the availability of life-saving drugs
[58]. In the face of impossible choices, informed policy is the last, best option.

4.6 Concluding Remarks
Work by generations of HIV researchers have pushed back against the pandemic,
developing effective therapies and multinational eradication strategies. The number of
new infections drops each year as those with the disease can live longer and healthier
lives. While HIV is no longer the global menace it once was, it remains fundamentally
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important to understand how the different forms of the disease manifest. In order to
understand the details of HIV disease, explorations of the immune cells depleted may
provide clarity in a search for a vaccine or future treatment. Finally, illustrating the
differences between diseases caused by the North American forms of the virus and those
found in Africa may prompt future research efforts to identify mechanisms and impacts
of the work presented.

.
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Appendix A
Sharing of equipment used for the preparation of a
controlled-release oral opiate for injection is associated with
HIV transmission
5.1 Preface
During my graduate research I was lucky to collaborate with multiple institutions and
groups of researchers on many HIV-focused projects. Fortunately, I had the greatest
involvement in a collaboration with the London Health Science Center, University
Hospital, and St. Joseph’s Hospital. The city of London, Ontario was experiencing an HIV
outbreak linked to injection drug use and clinicians were looking for basic science
collaborators to experimentally examine the feasibility of their hypotheses. I’ve included
the subsequent manuscript from this collaboration because of its importance in my graduate
work despite its incongruity with the HIV diversity project presented above.

5.2 Abstract
In London, Canada, an outbreak of HIV among people who inject drugs (PWID) occurred
despite widespread distribution of sterile needles, syringes and IDPE. Hydromorphone
controlled-release capsules (HCR) are the local opioid of choice (followed by immediaterelease hydromorphone) and is associated with frequent reuse and sharing of IDPE. Sharing
of needles/syringes is a known and well documented mechanism for transmission of HIV
amongst persons who inject drugs (PWID). Injection drug preparation equipment (IDPE;
i.e., cookers, filters) are more often shared than needles/syringes, but the risk of HIV via
this mode of transmission is unknown. The objective of this study was to determine
whether the practice of sharing injection drug preparation equipment (IDPE) to inject
controlled-release opiates is associated with HIV transmission; and to examine the
properties of controlled-release opiates that may lead to both IDPE sharing and HIV
transmission.

137

A case control study of HIV infected and HIV uninfected PWID cases was conducted using
a questionnaire to examine behaviors associated with injection drug use. The primary
exposure of interest was IDPE sharing over the last three months. To assess motivation to
share/reuse IDPE, residual opioid left in the IDPE after aspiration with a needle/syringe
was measured in conditions replicating PWID practices using liquid chromatography–
tandem mass spectrometry. To assess conditions favouring HIV transmission, HIV was
added to IDPE in the presence or absence of opioid. HIV viral persistence was then
measured in IDPE by HIV reverse transcriptase activity and infectivity of indicator Tzmbl cells. All experiments were done with HCR versus immediate-release hydromorphone
and a control.
Sharing IDPE (without sharing needles/syringes) was associated with HIV infection
[aOR=22.1; p<0.001]. IDPE reuse was almost universal among HCR users [31/31 (100%)
HIV+ and 62/66 (94%) HIV–]. Patient report of barriers and negative beliefs regarding
heating HCR in the IDPE was also associated with HIV infection (p<0.05). Approximately
45% of HCR remained in the IDPE following initial injection, with no change after heating,
whereas only 16% of immediate-release hydromorphone was retained. HIV reverse
transcriptase activity and infectivity were preserved in IDPE in the presence of HCR, but
not in the presence of immediate-release hydromorphone. Heating the IDPE rapidly
inactivated HIV despite the presence of residual HCR.
IDPE sharing is associated with HIV infection. Hydromorphone controlled-release
preparation leaves a significant drug residue in IDPE which encourages IDPE reuse and
sharing among PWID. HCR excipients preserve HIV viability which could potentiate HIV
transmission in this population. Heating IDPE prior to drug aspiration may be an effective
harm reduction strategy.

5.3 Introduction
Injection of prescription opioids has reached epidemic levels, resulting in an almost
fourfold rise in hospital admissions in the United States between 2004-2014 [1]. This
epidemic has also been associated with several large outbreaks of HIV [2,3] infection
among people who inject drugs (PWID), including one in London, Ontario that resulted in

138

the declaration of a Public Health emergency (June 14, 2016) (Figure 1) [4]. The control
of these outbreaks generally depends on a multi-pronged approach of needle distribution,
opiate substitution therapy, and provision of antiretroviral therapy. Our outbreak was
unusual as it occurred despite London already having at baseline the highest distribution
of sterile needles and syringes per capita in Canada, and an opiate substitution therapy
prescription rate in the top quartile for Ontario [5]. As well, London has a governmentfunded, multidisciplinary HIV care program with access to funded HIV antiretroviral
therapy. The reason for this outbreak despite the excellent pre-existing control programs
was the subject of this investigation.
A study of injection drug users in London identified hydromorphone controlled-release
(HCR) capsules (Hydromorph Contin® [marketed as Palladone SR® in Europe], Purdue
Pharma, Stamford CT, and marketed as Jurnista® in Australia, Janssen-Cilag Pty Ltd, High
Wycombe, UK.) as the preferred opioid for illicit use.6 The majority of PWID (79%)
reported HCR use in the past six months [6]. In addition, prescription rates of HCR capsules
are unusually high in London compared to other regions in Ontario, which may indicate
widespread availability of the drug for illicit use [5].
HCR capsules have a low solubility in water, and thus preparation of the drug for injection
requires numerous steps (Figure 2) [7]. First, the time released beads must be removed
from the capsule and crushed, then mixed with water in a cooker to create a slurry, and
then drawn into a syringe through a cotton filter to remove visible particulate matter (Figure
2) [7]. The filters, cookers and water are referred to as the injection drug preparation
equipment (IDPE). The large dose of hydromorphone in the controlled-release formulation
and the need to dissolve the capsule in a large volume of water increases the likelihood that
the residual drug will be shared between users [7]. In addition, patients report large
amounts of non-solubilized drug are retained in the filter and cooker after the first use,
thereby encouraging the reuse and/or sharing of used IDPE [7,8]. Reuse of IDPE is done
by adding water to the previously used cooker with residual drug still inside, placing a
needle into the previously used filter and aspirating the residual drug (“doing another
wash”) (Figure 2).
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Sharing of needles/syringes amongst persons who inject drugs has been well established as
a means of HIV transmission [9]. Thus, distribution of sterile needles/syringes has been a
major focus of HIV prevention programs. However, sharing of IDPE is more common than
sharing of needles/syringes [10–14]. In some centers, sharing of IDPE has been identified
as the primary risk factor for Hepatitis C (HCV) transmission [10,15–17]. The incentives
for sharing IDPE despite the existence of free IDPE distribution programs, and the impact
of IDPE sharing on HIV transmission, have not been extensively studied. We propose that
IDPE may initially become contaminated with HIV via a used needle from a PWID who
reuses their own needle [18,19] and then HIV is transmitted when the IDPE is shared with
a second user placing their own needle into the used filter/cooker to aspirate another
“wash”. We further hypothesized that heating the contaminated IDPE prior to each use
could inactivate HIV and help prevent transmission.
The objectives of this study were to clarify the following: (1) whether sharing IDPE is
associated with HIV infection, (2) the amount of residual hydromorphone in IDPE after
the first injection [and thus the incentive for reuse or sharing of IDPE] and the effects of
heating of the IDPE on the amount of hydromorphone available for injection, (3) the
persistence of HIV in IDPE and the efficacy of heating to inactivate HIV to prevent
transmission.

5.4 Methods
5.4.1 Setting
The HIV outbreak in London, Ontario, was confirmed by comparing new diagnoses
provided by the local Public Health Unit to regional and provincial figures. Cases were
referred to as incident infections if no previous positive result for HIV serology or HIV
viral load testing was available in the provincial database. Sociodemographic
characteristics and risk factors for incident HIV cases were determined by reporting on the
province wide, standardized serological HIV testing form.
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5.4.2 Association Between Sharing IDPE and HIV Infection
A case-control study of HIV-infected (HIV+) and HIV-uninfected (HIV-) injection drug
users was conducted to examine whether sharing IDPE is associated with HIV infection.
The primary exposure of interest was IDPE sharing within the last 3 months. Inclusion
criteria were age >17 years, residence in London-Middlesex county, Canada, and reported
injection drug use within the last three months. A total of 127 participants were recruited
from two sites: A) consecutive patients admitted to one of two local hospitals with a
diagnosis of injection drug use associated endocarditis (as these were patients with high
risk injection practices) and B) from a local needle exchange (where sterile
needles/syringes/cookers/filters and sterile water were distributed). Recruitment occurred
between August 11, 2016 and June 7, 2017. Routine HIV testing was performed using rapid
diagnostic tests at the safe injection site and fourth generation testing at the hospital sites.
Participants completed a detailed questionnaire regarding injection behaviors. The study
was approved by the Research Ethics Board, Western University. Written informed consent
was obtained from all participants.

5.4.3 Power Calculation
Based on a previous study that found a 40% prevalence of sharing IDPE amongst those
injecting hydromorphone controlled-release [8], we estimated an exposure prevalence of
20% in controls and 50% in cases, corresponding to an odds ratio of 4.0. A minimum of
33 cases and 66 controls were needed to detect this association between sharing IDPE and
HIV status, with 80% power, a 2-tailed alpha of 5%, and the continuity correction [20].
Final recruitment was 35 cases (HIV+) and 84 controls (HIV-).
Analyses were conducted using SAS 9.4 (SAS Institute Inc. Cary, NC, USA).
Sociodemographic characteristics and reported sharing behaviors between cases and
controls were compared using logistic regressions. Chi-square tests were used to compare
other categorical variables such as multiple washes of IDPE, and attitudes and beliefs about
heating. Multivariable logistic regressions were conducted for the primary exposure of
interest: IDPE sharing. If the addition of any sociodemographic variable demonstrated a
confounding influence (>10% change), or interaction with, the IDPE sharing parameter
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estimate, or if it was a significant independent predictor itself, it was retained in the
multivariable models. Variables that met these criteria included: employment, housing,
LGBTQ, and MSM; only housing and MSM were retained in the multivariable model as a
result of multicollinearity with employment and LGBTQ variables, respectively. Twotailed tests were employed, and the level of significance was set to 0.05.

5.4.4 Residual Hydromorphone in IDPE & Effects of Heating on
the Amount of Hydromorphone Injected
All experiments were performed with unused needles/syringes and IDPE equipment
(sterile water, cookers, filters) (Sterifilt Apothicom, Paris, Fr) that were distributed as part
TM

of the provincial harm reduction program, and thus commonly used by local PWIDs. To
quantify the amount of residual drug present in the cooker and filter after an initial
injection, we replicated the technique of crushing the drug, placing it in a cooker, dissolving
it in water, and aspirating the solution through a filter (Figure 2). We developed this
technique in consultation with local PWIDs. We performed this experiment with
hydromorphone controlled-release capsule (24 mg) (Purdue Pharma, Stamford, CT)
and immediate-release hydromorphone tablet (8 mg) (Pharmascience Inc., Montreal, PQ)
as they are the doses and preparations most commonly injected locally. Hydromorphone
concentrations were measured using liquid chromatography–tandem mass spectrometry
(LC-MS/MS). The effect of heating on drug stability was examined by heating the
preparation with a cigarette lighter until bubbles formed.
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Figure 5.1) Incidence and count of HIV infection in Middlesex-London and Ontario,
2005-2017. The Ontario (ON) and Middlesex-London (ML) HIV rates (per 100,000) are
shown in the red and green lines respectively. Middlesex-London HIV incident cases per
year are shown in the green bars. * denotes significantly higher (p<0.05) incidence of HIV
in Middlesex-London relative to Ontario.
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5.4.5 HIV Persistence in IDPE & Effects of Heating on HIV
All experiments with replication competent HIV-1 were performed in a BSL2+ facility
with appropriate safety and waste protocols. Hydromorphone controlled-release capsules
and immediate-release hydromorphone tablets were prepared as above (schematic in
Figure 1). Two controls were used for each experiment 1) 250 mg of the excipient
microcrystalline cellulose (Sigma) was added to the cookers, or 2) the cookers remained
empty. Microcrystalline cellulose is a common filler/stabilizer in controlled-release drug
formulations including hydromorphone controlled-release. HIV-1 (CXCR4 tropic
genotype #1389) at titer of 1*108 infectious particles per mL was diluted 1:5 in sterile water
(Sigma) and 1.5 mL was added to each cooker.
Following a five-minute, room temperature incubation, the water was aspirated through the
filter with a syringe (sans needle per containment lab requirements). This injectate
preparation protocol was repeated with serial washes at 1 hour, 4 hours, 24 hours, 48 hours,
and 72 hours for a total of six preparations for each filter. Filters were collected after the
final aspiration. Insoluble residual material from the hydromorphone controlled-release
and microcrystalline cellulose cookers was collected after the 24, 48, and 72-hour time
points (50 mg per time point). To measure HIV viral persistence, injectates were split into
aliquots for HIV reverse transcriptase and infectivity assays using Tzm-bl cells. Protocols
for these assays have been previously published [21].
To assess the effects of heating on HIV persistence, cookers were heated with an ethanol
flame until bubbles formed around the edge of the cooker. All laboratory experiments were
performed in triplicate with standard error bars displayed. Heating experiments were
performed according to BSL2+ safety protocols in a biosafety cabinet with an ethanol
flame. Cookers were heated until bubbles formed around the edge of the cooker.
Prior to 2012, the filters distributed by harm reduction sites in Ontario were originally
intended for the dental industry. These filters are made of rolled, less dense cotton with no
chemical binding agents, additives, or whiteners (Maxill 53190). The filters distributed
since 2012 are made of pressed cotton and coated with methylethyl-cellulose (Apothicom,
France). Filters were cut to normalize by weight between generations.
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Figure 5.2) Method for preparing Hydromorphone controlled-release for injection. 1) Open hydromorphone controlled-release
capsule and empty time release beads into a pill crusher to crush the beads. Crush beads into a fine dust. Many individuals opt to use
the bottom of a disposable lighter or the tops of syringe plungers to crush the beads as opposed to a pill crusher. Empty the crushed
beads into a cooker. 2) Place a cotton injection filter into the solution. 3) Add approximately 1.5mL of water to the cooker. Allow cooker
to sit for 5 minutes at room temperature to dissolve the opioid. 4) Draw up the solution into a syringe and inject. 5) Individuals usually
opt to perform multiple “washes” whereby further water is added to the residual drug in the cooker/filter and the used needle is
reintroduced into the same filter. The individual will then draw the additional drug solution and re-inject. Multiple users may participate
with “serial washes” using the same filter/cooker/crushed-drug complex and patients reusing their own needle/syringe into a common
filter.
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5.4.6 Community Interventions
Based upon the results of the above investigations a community education project was
carried out starting on June 15, 2017. This involved peer mentors, injection equipment
distribution staff and public health officials spreading a message to PWIDs to “cook your
wash” ie heat the IDPE containing the drug and filter and water, with a cigarette lighter
until bubbling prior to any injection of hydromorphone. Local mass media was also used
to spread this message (see “London researchers may have pinpointed why rates of HIV,
other diseases rising among drug users” in the London Free Press, October 27 th, 2017). In
October 2017, a program of health care navigators to enable HIV infected patients to attend
their medical appointments was initiated. These staff were also involved in the education
campaign.

5.5 Results
HIV incidence in London rose above that in other regions of Ontario in 2015 and 2016
(Figure 1) (p<0.05). The incidence remained high in early 2017 but fell in the latter half of
2017 and was no longer significantly different from that of Ontario for 2017 as a whole.
Data from 2016 suggested that the most frequently reported exposure category among new
HIV cases in London was “injection drug use” (n=45/60; 75%), whereas <10% of new HIV
cases occurred amongst persons who inject drugs in the same time period in the rest of
Ontario. Mean age of new HIV cases was 37.6 years (SD=9.7). Sixty four percent were
male.

5.5.1 Association Between Sharing IDPE and HIV Infection
One hundred and twenty-seven patients were recruited into the case control study. Eight
participants were excluded due to unknown HIV status. The remainder were divided into
cases (HIV infected; n=35) and controls (HIV uninfected; n=84).
Cases (HIV+) and controls (HIV–) for this study were all persons who inject drugs, living
in London, and were similar with regards to age, sex, housing status, race, employment,
and recent endocarditis (Table 1). There was no difference in the proportion of inpatients
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(recruited from the hospital site) and participants recruited at the safe-injection site, in the
case and control groups.
Unadjusted (Table 1) and adjusted (Table 2) models showed that HIV infection was
strongly and consistently associated with sharing IDPE among persons who inject drugs.
HIV infection was associated with men-who-have-sex-with-men status, although the
association was weaker than sharing of IDPE. Sharing needles/syringes in the absence of
IDPE sharing was not associated with HIV status. Removing either MSM status or housing
status from the regression model did not change the results.
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Table 5.1) Characteristics of HIV infected and HIV uninfected Persons Who Inject
Drugs

Case (HIV +) Control (HIV –)
Odds Ratio (95%
(n = 35)
(n = 84)
Confidence Interval)
Injection Equipment Sharing1
None

14 (42%)

61 (73%)

Reference

Only needles/syringes

4 (12%)

16 (19%)

1.09 (0.32, 3.76)

Only IDPE#

10 (30%)

3 (4%)

14.52 (3.53, 59.77)*

Both IDPE# and
needles/syringes

5 (15%)

3 (4%)

7.26 (1.55, 34.03) *

Sociodemographic factors
Age

38.4 (10.2)

^

41.2 (10.5)

^

1.03 (0.99, 1.07)

Female

6 (17%)

21 (25%)

0.62 (0.23, 1.70)

MSM2

5 (18%)

2 (3%)

6.63 (1.20, 36.60) *

LGBTQ3

3 (12%)

7 (9%)

1.29 (0.61, 5.39)

Stable housing4

19 (54%)

34 (41%)

1.71 (0.77, 3.79)

Aboriginal
(REF=Caucasian)5

9 (26%)

17 (21%)

1.33 (0.53, 3.39)

Stable employment6

2 (6%)

5 (6%)

1.02 (0.19, 5.53)

Endocarditis

9 (25%)

14 (17%)

1.73 (0.67, 4.48)
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Injection drug use
Hydromorphone
controlled-release

31 (89%)

66 (79%)

2.11 (0.66, 6.77)

Immediate-release
hydromorphone

20 (57%)

64 (76%)

0.42 (0.18, 0.96) *

Methamphetamine

27 (77%)

63 (75%)

1.13 (0.44, 2.85)

* Highlights significant values
#
IDPE= Injection Drug Preparation Equipment
^
Standard Deviation
Sharing data available for 33 cases and 83 controls
MSM (men who have sex with men) data available for 28 cases and 63 controls
LGBTQ (lesbian, gay, bisexual, transgender and queer) data available for 26 cases and 76 controls
Housing data available for 35 cases and 83 controls
Race data available for 34 cases and 80 controls
Employment data available for 33 cases and 84 controls
Note: MSM defines a behaviour while LGBTQ is an umbrella term for many sexual and gender identities
1
2
3
4
5
6
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Table 5.2) Associations of HIV status with injecting behavior and Risk Factor variables.
Logistic Regression.
Odds Ratio (95% CI)
Sharing (Ref=neither)

p value
<.001

Both IDPE and needle/syringes

23.88 (2.36, 241.82)

.007

Only IDPE

22.12 (4.51, 108.59)

<.001

0.91 (0.16, 5.37)

0.92

11.34 (1.79, 71.69)

0.01

1.83 (0.55, 6.10)

0.32

Only needle/syringes
MSM
Stable housing

Adjusted odds ratio (OR) and associated 95% confidence interval (CI) are presented
IDPE: injection drug preparation equipment; MSM: men who have sex with men
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5.5.2 Residual Hydromorphone in IDPE & Effects of Heating on
the Amount of Hydromorphone Injected
Forty-five percent of the total hydromorphone in the hydromorphone controlled-release
capsule remained in the IDPE after the first aspiration (and thus was available for use in a
subsequent “wash”), whereas only 16% remained in the IDPE when using immediaterelease hydromorphone tablets (Figure 3). Heating during the injection preparation did not
significantly change the amount of hydromorphone controlled-release in the injectate or
the amount recovered from the IDPE (Figure 3). The preparation boiled (reached bubbling)
in less than 10 seconds when using a cigarette lighter.
Patient behavior reflected the findings of high drug residual in hydromorphone controlledrelease preparations. The case control subjects reported performing multiple washes of
used IDPE more frequently when using hydromorphone controlled-release than with other
drugs. Multiple washes were reported when using hydromorphone controlled-release
[93/97 (96%) (of whom 31/31 HIV+, and 62/66 controls)], in comparison to immediaterelease hydromorphone [41/84 (49%) (12/20 HIV+, and 29/64 controls); p<0.001] and
crystal methamphetamine [19/92 (21%) (9/29 HIV+, and 10/63 controls); p<0.001]
(denominators reflect number of patients using the respective drug in each group).
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Figure 5.3) Relative amount of hydromorphone recovered in syringe (injectate
sample) and injection drug preparation equipment (filter and residue samples) with
and without heating with A) 24mg of hydromorphone controlled-release and B)
Immediate-release hydromorphone 8mg. Error bars represent standard error.
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5.5.3 HIV Persistence in IDPE & Effects of Heating on
Persistence
Simulating drug preparation habits with a known inoculum of HIV-1 (Figure 2) allowed
us to quantify relative viral persistence in different IDPE environments (Figure 4). Tzm-bl
cells are highly susceptible to HIV infection and were used to quantify viral infectivity in
the injectate samples under conditions employed by PWIDs. When preparing HCR for
injection, infectious HIV was recovered from the zero-, one-, and four-hour time points,
representing washes one, two, and three of HIV-inoculated IDPE. Significantly less
infectious HIV was recovered from HIV-inoculated IDPE used when preparing immediaterelease hydromorphone compared to hydromorphone controlled-release. Infectious HIV
recovery was intermediate from HIV-inoculated IDPE that contained microcrystalline
cellulose as a control (Figure 4A).
The limiting sensitivity of the Tzm-bl assay prevented us from measuring infectivity
beyond four hours (third wash). Previous work has indicated that reverse transcriptase
activity in HIV-1 is a strong predictor of virus infectivity and has greater
sensitivity/specificity than other surrogate assays such as p24 ELISAs or viral RNA load
[22]. In the presence of HCR, and to a lesser extent microcrystalline cellulose, HIV reverse
transcriptase activity persisted in the filters for 72 hours after inoculation and six serial
washes, whereas HIV was not detected in the same conditions when originally mixed with
immediate-release hydromorphone or the water control (Figure 4B).
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Figure 5.4) Infectious HIV
persistence after addition to
Injection
Drug
Preparation
Equipment.
A) Infectivity of HIV-1 in injectates
as determined by Tzm-bl cell
luciferase production. HIV-1 was
spiked into cookers containing
opioids and expedients to measure
viral persistence. Serial washes with
sterile water were collected 5
minutes, 1 hour and 4 hours post
addition of virus.
Maximal
preservation of infectivity over time
seen
with
Hydromorphone
controlled-release
across
all
measured timepoints. Error bars
represent
standard
error.
*
significant at p<0.05 via two-way
ANOVA with Tukey’s correction
for multiple comparisons. B) HIV-1
reverse transcriptase activity after 72
hours in injectates (after 6 washes).
Only hydromorphone controlledrelease
and
Microcrystalline
Cellulose continued to show abovebackground reverse transcriptase
activity at this last timepoint.
Dashed lines represent assay
detection limits. Error bars represent
standard error. * significant at
p<0.05 via two-tailed t-tests.
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Figure 5.5) Reduction in infectious HIV-1 (measured via Tzm-bl cell luciferase
production) after 10 second heat treatment. HIV-1 was added to cookers containing
hydromorphone controlled-release 24mg and an Apothicom filter and washed with sterile
water (Injectate Washes 1 & 2 were collected 5 minutes and 1 hour after HIV-1 addition
respectively). Cookers were then heated above an ethanol flame for 10 seconds or left at
room temperature. Persisting infectious HIV-1 was quantified via luciferase production
from Tzm-bl cells. Dashed line represents assay detection limit. Error bars represent
standard error. ** significant at p<0.001 via two-tailed t-test.
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To identify the location of the HIV-1 reservoir in the IDPE, we measured reverse
transcriptase activity in the insoluble drug material and filters independently, both
“housed” in the cooker, after 72 hours. Higher levels of reverse transcriptase activity (i.e.
HIV) were observed in the filters in the presence of hydromorphone controlled-release
compared to the other compounds (Supplemental Figure 1). Heating the cooker liquid with
HCR or hydromorphone immediate-release to a boil reduced the residual HIV-1 titers
(infectious or reverse transcriptase activity) by two logs, to the limits of detection (Figure
5).

5.6 Discussion
5.6.1 Association Between Sharing IDPE and HIV Infection
We demonstrate that sharing of IDPE among injection drug users was a strong risk factor
for HIV infection. We cannot differentiate risk associated with specific drug preparation
equipment (i.e., filters versus cookers, rinse water, or residual drug), as these items are
almost always used and shared concurrently [17]. However, the significant amount of
viable virus found within the filters at 72 hours suggests that inserting an unused needle
into a shared filter could lead to infection (Supplemental Figure 1). We also found that
sharing both IDPE and needles/syringes was associated with an increased risk of HIV
transmission. However, this result was likely driven by sharing IDPE, as sharing
needles/syringes alone was not a significant factor in HIV infection in our study, and the
adjusted odds ratio (aOR) of sharing both IDPE and needles/syringes was similar to that of
sharing IDPE alone. Sharing of needles and syringes has been shown to be a risk for HIV
infection in other settings, however our study occurred in an area with an exceptionally
large needle/syringe distribution program enabling assessment of the impact of IDPE
sharing when needle/syringe sharing is relatively infrequent. In contrast to our study, a
recent HIV outbreak in Indiana demonstrated a 90% rate of needle/syringe sharing amongst
HIV+ patients and 66% amongst HIV negative controls during the outbreak. Our much
lower rates of needle/syringe sharing allowed the impact of IDPE sharing to be detected.
Therefore, as needle/syringe distribution programs are rolled out, interventions to prevent
HIV transmission associated with IDPE sharing will become increasingly important to
eliminate further HIV transmission.
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As in previous studies [8,10,12–14] we found that sharing filters and other IDPE occurs
often. This is likely because the risk of HIV transmission with IDPE is not
recognized. Participants who avoided needle/syringe sharing frequently reported IDPE
sharing several times per day. Those who share needle/syringes likely do so very rarely,
due to the known significant associated risk. Therefore, even if the risk of HIV infection
associated with a single episode of needle/syringe sharing may be higher than that of a
single episode of IDPE sharing, the high frequency of IDPE sharing contributes to a greater
cumulative risk. We also suspect that due to awareness of the risks associated with
needle/syringe sharing, individuals may only do so with partners whom they believe are
sero-concordant. Due to a lack of awareness of the risk associated with IDPE sharing, we
believe that individuals do not avoid this behavior, nor do they attempt to sero-sort with
IDPE sharing. Further studies are necessary to confirm this hypothesis.

5.6.2 Residual Hydromorphone in IDPE
These results provide the first evidence that 45% of the contents of a hydromorphone
controlled-release capsule remain in the IDPE after an initial use, thereby incentivizing the
behavior of frequent reuse of the IDPE to access retained HCR. The local street value of a
capsule of hydromorphone controlled-release is approximately $60 CAN ($45.60 US) and
therefore, disposal of the remaining drug in the IDPE is very uncommon. This leads to
IDPE being commonly shared and sold among persons who inject drugs, despite nearly
exclusive use of fresh needles/syringes [7]. In contrast, the low quantity of residual
immediate-release hydromorphone on the IDPE, due to its lower dose and the high
solubility of immediate release opioids, provides less incentive to reuse the IDPE. Our
study confirmed that reuse was indeed most common with hydromorphone controlledrelease and less common with hydromorphone immediate-release or crystal
methamphetamine.

5.6.3 HIV Persistence in IDPE
It has previously been demonstrated that HIV RNA can be found in high titer in IDPE used
by persons who inject drugs, although the specific drugs used and their relative abilities to
preserve HIV were not described in these studies [18,19]. HIV survival has been found to
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be reduced in the presence of heroin, but it is unclear whether this was related to the heating
process required for home production or the many caustic chemicals added to produce the
solution [23]. To our knowledge, this study is the first to assess HIV persistence in the
presence of prescribed opioids that do not require heating or the addition of extra chemicals
for solubility. We demonstrated prolonged HIV survival in IDPE used in the preparation
of controlled-release opioid (up to 3 days) compared to that used for an immediate-release
opioid preparation. The dual effect of a controlled-release opioid which not only increases
HIV survival in IDPE but is also retained, thereby providing an incentive for sharing IDPE,
appears to be synergistic in facilitating HIV transmission.
HIV persistence may be related to excipients in the long-acting preparation, as persistence
was not seen with hydromorphone immediate-release tablets. Specifically, excipients in
hydromorphone controlled-release that are not in immediate-release hydromorphone
include ethyl cellulose, hydroxypropyl methylcellulose, and microcrystalline cellulose.
Addition of microcrystalline cellulose alone to the IDPE retained more viable HIV and for
longer than IDPE used with water or IDPE used with immediate-release hydromorphone.
We were unable to obtain pure hydromorphone in the absence of the other constituents in
the formulation, which affected our ability to determine if the drug alone impacts HIV
viability and retention on the IDPE. However, we believe that it is more likely that
excipients in the long-acting drug preparations may contribute to HIV persistence.
Cellulose-containing drugs may maintain hydration, resulting in virus preservation. In fact,
methyl cellulose derivatives are a major constituent in media to maintain hydration and
limit diffusion for viral plaque assays used for clinical diagnostics [24].

5.6.4 Harm Reduction Implications
While HIV transmission from sharing needles/syringes has been well established,

9

transmission associated with sharing IDPE in the absence of needle/syringe sharing has
only been suggested [25,26]. As a result, harm reduction education for persons who inject
drugs often emphasizes the risk of sharing needles/syringes, but not IDPE. Future harm
7

reduction education should emphasize the importance of not sharing IDPE, as this behavior
could reduce the incidence of HIV among persons who inject drugs. However, it is unlikely
that a campaign focusing on the prevention of IDPE sharing alone would be successful,

158

given the economic pressures to maximize utilization of the very expensive residual
hydromorphone.
We found that HIV+ cases were more likely to believe that heating hydromorphone during
preparation was not necessary or was harmful to drug availability (believing it “boiled off
the dope”). A previous study showed that HIV is inactivated with heating IDPE, although
this was not studied in the presence of prescribed opioids [27]. We demonstrated that
heating IDPE until boiling is an effective means of inactivating HIV, even in the presence
of a controlled-release opioid. Heating maintained the same dose of active hydromorphone
in the injectate, and therefore would not contribute to increased rates of overdosing or
discourage drug users who are afraid of reducing drug availability. Thus, HIV transmission
may be attenuated by promoting the message to “cook the wash” (i.e. heat the wash with a
lighter until bubbling) if reusing IDPE.
Based upon the results of the above investigations a community education project was
carried out starting on June 15, 2017. This involved peer mentors, injection equipment
distribution staff, HIV healthcare navigators, and public health officials spreading a
message to PWIDs to “cook your wash” i.e., heat the IDPE containing the drug and filter
and water with a cigarette lighter until bubbling prior to any injection of hydromorphone.
Local mass media was also used to spread this message. Results of this campaign will be
presented at a later date.
Using a sterile needle for every aspirate of a drug is also useful in preventing viral
contamination of the IDPE, but this alone will not reduce the risk of bacterial contamination
of the injectate from repeated handling; boiling is necessary to reduce this potential
bacterial load (data not shown). Cleaning the IDPE with bleach prior to reuse has been
occasionally recommended, although it would not be acceptable in the context of retained
drug and injectate being exposed to the caustic effects of bleach. Recognizing that the
formulation of hydromorphone controlled-release is a specific risk factor for reuse, the
provision of injectable hydromorphone should also be considered, as per the SALOME
trials [28].
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5.6.5 HIV Transmission in Other Regions
We suspect that HIV transmission in association with sharing IDPE may be occurring in
other regions as well. There have been several recent large injection drug use-associated
HIV outbreaks including an ongoing outbreak in Saskatchewan, where hydromorphone
controlled-release is the opioid of choice [30]. Similarly, the opioid of choice in a recent
outbreak in Indiana was a controlled-release preparation containing microcrystalline
cellulose [oxymorphone hydrochloride extended-release (Opana ER ®, Endo International
PLC, Malvern Pennsylvania)]; [31] a drug that has also been associated with IDPE sharing
and HCV transmission [2,10,31]. The risk of HIV and HCV infection associated with illicit
use of oxymorphone extended-release resulted in its removal from the US market [29],
although it is still available in Canada and Europe.

5.6.6 Study Limitations
The major exposure of interest was sharing of IDPE. As this was identified retrospectively
in a case control design, the possibility of recall bias cannot be ruled out. However, it is
notable that HIV infected patients were no more likely to recall sharing of needles/syringes
than HIV uninfected patients and so we do not believe that recall bias was leading case
patients to non-specifically report more risky behaviors.
As the focus of this study was on HIV transmission associated with Injection Drug Use,
some sexual risk factors for HIV were not fully investigated (e.g. unprotected sex, multiple
partners). Report of beliefs and attitudes regarding heating IDPE prior to injection was not
available for several participants, and so this could not be placed into the multiple
regression analysis and only an unadjusted analysis of these data could be presented.
Hydromorphone immediate-release use was associated with a protective effect in
unadjusted analysis, as it tends to be used by local persons who inject drugs in substitution
for Hydromorphone controlled-release when the latter is unavailable or unaffordable.
Therefore, increased hydromorphone immediate-release use would suggest decreased
controlled-release availability, and we believe that the controlled release formulation was
most important in transmission.
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5.7 Conclusion
The recent outbreaks of HIV in PWID emphasize the need for understanding all
mechanisms of transmission and the development of new tools in the fight against HIV
transmission in this population. This community suffered an outbreak of HIV despite
having excellent pre-existing traditional programs for harm reduction and HIV prevention.
Our data demonstrated that the widespread local abuse of a controlled release opioid which
encouraged reuse and sharing of IDPE when injecting, and the increased HIV survival in
the IDPE, contributed to the significant infectiousness of the practice. Preventing IDPE
sharing will be difficult due to the retention of valued drug in the IDPE after use. Heating
IDPE prior to each use may provide an effective harm reduction approach to reducing HIV
infection. As the popularity of injecting prescription opioids continues to increase [5,30],
implementation of harm reduction strategies that target sharing IDPE as a mechanism of
transmission will become increasingly important.
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Supplementary Figure 5.1) Preservation of infectious HIV in Injection Drug
Preparation Equipment with different Filters and Opiate Preparations
A) HIV-1 was spiked into IDPEs
with varying opioids and syringe
filters
to
measure
viral
persistence. HIV-1 isolated from
the syringe filters after 72 hours
was quantified via Reverse
Transcriptase
assay.
*
significant at p<0.05, **
significant at p<0.01 via twoway ANOVA with Tukey’s
correction
for
multiple
comparisons. B) HIV-1 isolated
from the injectates pulled
through each filter type after 72
hours was quantified via Reverse
Transcriptase
assay.
Apothicom® filters are made of
tightly woven cotton coated in
methylethyl-cellulose
while
dental filters are loosely woven,
undyed cotton. Virus Reverse
Transcriptase activity was best
preserved
using
Hydromorphone
controlledrelease and Apothicom® filters.
Dashed line represents assay
detection limit. Error bars
represent standard error. *
significant at p<0.05, ** at
p<0.001 via via two-way
ANOVA
with
Tukey’s
correction
for
multiple
comparisons.
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Injection Drug Preparation Equipment. Journal of AIDS. Mar 2019.
Gibson RM, Nickel G, Crawford M, Kyeyune F, Venner C, Nankya I, Nabulime
E, Ndashimye E, Poon AFY, Salata RA, Kityo C, Mugyenyi P, Quiñones-Mateu
ME, Arts EJ. Sensitive detection of HIV-1 resistance to Zidovudine and impact on
treatment outcomes in low- to middle-income countries. Infect Dis Poverty. 2017
Dec 4;6(1):163. doi: 10.1186/s40249-017-0377-0.
Venner CM, Nankya I, Kyeyune F, Demers K, Kwok C, Chen PL, Rwambuya S,
Munjoma M, Chipato T, Byamugisha J, Van Der Pol B, Mugyenyi P, Salata RA,
Morrison CS, Arts EJ.Infecting HIV-1 Subtype Predicts Disease Progression in
Women of Sub-Saharan Africa. EBioMedicine. 2016 Nov;13:305-314. doi:
10.1016/j.ebiom.2016.10.014.
Asmal M, Lane S, Tian M, Nickel G, Venner C, Dirk B, Dikeakos J, Luedemann
C, Mach L, Balachandran H, Buzby A, Rao S, Letvin N, Gao Y, Arts EJ.
Pathogenic infection of Rhesus macaques by an evolving SIV-HIV derived from
CCR5-using envelope genes of acute HIV-1 infections. Virology. 2016
Dec;499:298-312. doi: 10.1016/j.virol.2016.09.021.
Kyeyune F, Gibson RM, Nankya I, Venner C, Metha S, Akao J, Ndashimye E,
Kityo CM, Salata RA, Mugyenyi P, Arts EJ, Quiñones-Mateu ME. LowFrequency Drug Resistance in HIV-Infected Ugandans on Antiretroviral
Treatment Is Associated with Regimen Failure. Antimicrob Agents Chemother.
2016 May 23;60(6):3380-97. doi: 10.1128/AAC.00038-16.
Venner CM, Ratcliff AN, Coutu M, Finzi A, Arts EJ. HIV-1 Entry and Fusion
Inhibitors: Mechanisms and Resistance. Curr Top Microbiol. 2015. doi:
10.1007/978-3-319-46718-4_36.
McCall AC, Murphy SJ, Venner C, Brown M. Florivores Prefer White Versus
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Pink Petal Color Morphs in Wild Radish, Raphanus sativus. Oecologia. 2013
May;172(1):189-95. doi: 10.1007/s00442-012-2480-z.
SCHOLARSHIPS AND AWARDS
International Ontario Graduate Scholarship (Provincial Award)
University of Western Ontario

2017-2018

R.G.E. Murray Fellowship (Institutional Award)
University of Western Ontario

2016-2017

R.G.E. Murray Travel Awards (Departmental Awards)
University of Western Ontario

2014-2018

Anderson Grant (Institutional Award)
Denison University

2008-2009

Battelle Memorial Institute Award (Institutional Award)
Denison University

2007-2008

PRESENTATIONS
Venner, C.M., Ball L, Koivu S, Tirona RG, Arts E, Wong R, Hallam B,
Silverman MS. 2018. HIV Infection Associated with Sharing Injection Drug
Preparation Equipment. Poster Presentation, Canadian Student Health Research
Forum, Winnipeg, MB.
Honorable Mention for Poster Presentation
Venner, C.M., Ball L, Koivu S, Tirona RG, Arts E, Wong R, Hallam B,
Silverman MS. 2018. HIV Infection Associated with Sharing Injection Drug
Preparation Equipment. Oral Presentation, Canadian Association for HIV
Research Conference, Vancouver, BC.
Venner, C.M., Nankya, I., & Arts, E.J. 2017. HIV Subtypes Display Differential
Receptor Binding and Entry Rates: Contributions to Pathogenesis. Oral
Presentation, Canadian Association for HIV Research Conference, Montreal, QC.
Venner, C.M., Nankya, I., & Arts, E.J. 2016. Slow disease progression of women
infected with HIV-1 subtype C versus subtype A and D: Implications for the
epidemic. Poster, Canadian Association for HIV Research Conference, Winnipeg,
MB.
Venner, C.M., Nankya, I., & Arts, E.J. 2015. Fitness, Pathogenesis and Entry
across HIV-1 Group M Subtypes. Oral Presentation, Infection and Immunity
Research Forum, London, ON.
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Second Prize for Oral Presentation
Venner, C.M., Nankya, I., & Arts, E.J. 2015. Slow progression of women
infected with HIV-1 subtype C versus subtype A and D. Poster, International
AIDS Society Conference, Vancouver, BC.
Venner, C.M., Nankya, I., & Arts, E.J. 2015. HIV-1 Group M subtypes display
differential rates of CD4 T-Cell decline. Poster, Canadian Association for HIV
Research Conference, Toronto, ON.
Venner, C., & McCall A.C. 2011. Does leaf damage induce anti-herbivore
defenses in Raphanus sativus petals or pollen? Poster, Ecological Society of
America Conference, Austin, TX.
Venner, C., & McCall A.C. 2009. Plant traits that affect pollination and seed set
in Echinacea angustifolia. Poster, Denison University Senior Research
Symposium, Granville, OH.
Venner, C., & McCall A.C. 2009. The Effects of Fragmentation on Pollination
Success in Echinacea angustifolia. Oral Presentation, Midwest Ecology and
Evolution Conference, Lincoln, NE.
TEACHING ASSISTANTSHIPS
Teaching Assistant - University of Western Ontario
Biological, Social, and Economic Determinants of Infectious Diseases
GHS3500 - Spring 2018
Bacterial Pathogenesis
MICRO4100 - Fall 2015, Fall 2016
Teaching Assistant - Denison University
Plant Evolution and Reproduction
BIOL326 – Spring 2009
Introduction to Biology
BIOL150 – Fall 2008

